IBD に関する主要な業績 2020 年 3 月現在
英文論文
1. Yamamoto T, Bain IM, Connolly AB, Keighley MR. Gastroduodenal fistulas in
Crohn’s disease: clinical features and management. Dis Colon Rectum 1998; 41:
1287-92.
2. Yamamoto T, Bain IM, Connolly AB, Allan RN, Keighley MR. Outcome ofstrictureplasty for duodenal Crohn’s disease. Br J Surg 1999; 86: 259-62.
3. Yamamoto T, Bain IM, Allan RN, Keighley MR. Persistent perineal sinus after
proctocolectomy for Crohn’s disease. Dis Colon Rectum 1999; 42: 96-101.
4. Yamamoto T, Keighley MR. Long-term results of strictureplasty without synchronous
resection for jejunoileal Crohn’s disease. Scand J Gastroenterol 1999; 34: 180-4.
5. Yamamoto T, Allan RN, Keighley MR. Perforating ileocecal Crohn’s disease does notcarry a high risk of recurrence but usually re-presents as perforating disease. Dis
Colon Rectum 1999; 42: 519-24.
6. Yamamoto T, Keighley MR. Long-term outcome of total colectomy and ileostomy for
Crohn disease. Scand J Gastroenterol 1999; 34: 280-6.
7. Yamamoto T, Keighley MR. Follow up of more than 10 years after strictureplasty for
jejunoileal Crohn’s disease: Long-term results and predictive factors for outcome.
Colorectal Dis 1999; 1: 101-6.
8. Yamamoto T, Bain IM, Allan RN, Keighley MR. An audit of strictureplasty forsmall-bowel Crohn’s disease. Dis Colon Rectum 1999; 42: 797-803.
9. Yamamoto T, Keighley MR. The association of cigarette smoking with a high risk ofrecurrence after ileocolonic resection for ileocecal Crohn’s disease. Surg Today 1999;
29: 579-80.
10. Yamamoto T, Keighley MR. Stapled functional end-to-end anastomosis in Crohn’sdisease. Surg Today 1999; 29: 679-81.
11. Yamamoto T, Allan RN, Keighley MR. Smoking is a predictive factor for outcome
after colectomy and ileorectal anastomosis in patients with Crohn’s colitis. Br J Surg
1999; 86: 1069-70.
12. Yamamoto T, Bain IM, Mylonakis E, Allan RN, Keighley MR. Stapled functional
end-to-end anastomosis versus sutured end-to-end anastomosis after ileocolonicresection in Crohn disease. Scand J Gastroenterol 1999; 34: 708-13.
13. Yamamoto T, Keighley MR. Long-term results of strictureplasty for ileocolonicanastomotic recurrence in Crohn’s disease. J Gastrointest Surg 1999; 3: 555-60.
14. Yamamoto T, Allan RN, Keighley MR. Strategy for surgical management of

ileocolonic anastomotic recurrence in Crohn’s disease. World J Surg 1999; 23:1055-61.
15. Yamamoto T, Keighley MR. Factors affecting the incidence of postoperative septic
complications and recurrence after strictureplasty for jejunoileal Crohn’s disease. Am
J Surg 1999; 178: 240-5.
16. Yamamoto T, Allan RN, Keighley MR. An audit of gastroduodenal Crohn disease:clinicopathologic features and management. Scand J Gastroenterol 1999; 34: 1019-24.
17. Yamamoto T, Keighley MR. Proctocolectomy is associated with a higher complication
rate but carries a lower recurrence rate than total colectomy and ileorectal anastomosis
in Crohn colitis. Scand J Gastroenterol 1999; 34: 1212-5.
18. Yamamoto T, Allan RN, Keighley MR. Audit of single-stage proctocolectomy for
Crohn’s disease: postoperative complications and recurrence. Dis Colon Rectum
2000; 43: 249-56.
19. Yamamoto T, Keighley MR. Fate of the rectum and ileal recurrence rates after total
colectomy for Crohn’s disease. World J Surg 2000; 24: 125-9.
20. Yamamoto T, Keighley MR. Smoking and disease recurrence after operation for
Crohn’s disease. Br J Surg 2000; 87: 398-404.
21. Yamamoto T, Allan RN, Keighley MR. Risk factors for intra-abdominal sepsis after
surgery in Crohn’s disease. Dis Colon Rectum 2000; 43: 1141-5.
22. Yamamoto T, Keighley MR. Enterovesical fistulas complicating Crohn’s disease:
Clinicopathological features and management. Int J Colorectal Dis 2000; 15: 211-5.
23. Yamamoto T, Allan RN, Keighley MR. Effect of fecal diversion alone on perianal
Crohn’s disease. World J Surg 2000; 24: 1258-63.
24. Yamamoto T, Mylonakis E, Keighley MR. Two surgical procedures for strictures at
Finney strictureplasty for small bowel Crohn’s disease. Dig Surg 2000; 17: 451-3.
25. Yamamoto T, Allan RN, Keighley MR. Long-term outcome of surgical managementfor diffuse jejunoileal Crohn’s disease. Surgery 2001; 129: 96-102.
26. Muñoz-Juárez M, Yamamoto T, Wolff BG, Keighley MR. Wide-lumen stapled
anastomosis vs. conventional end-to-end anastomosis in the treatment of Crohn’sdisease. Dis Colon Rectum 2001; 44: 20-6.
27. Yamamoto T, Mylonakis E, Keighley MR. Omentoplasty for persistent perineal sinus
after proctectomy for Crohn’s disease. Am J Surg 2001; 181: 265-7.
28. Ryan WR, Allan RN, Yamamoto T, Keighley MR. Crohn’s disease patients who quit
smoking have a reduced risk of reoperation for recurrence. Am J Surg 2004; 187:219-25.
29. Shatari T, Clark MA, Yamamoto T, Menon A, Keh C, Alexander-Williams J, Keighley

M. Long strictureplasty is as safe and effective as short strictureplasty in small-bowel
Crohn’s disease. Colorectal Dis 2004; 6: 438-41.
30. Yamamoto T, Umegae S, Kitagawa T, Matsumoto K. Mucosal cytokine production
during remission after resection for Crohn’s disease and its relationship to future
relapse. Aliment Pharmacol Ther 2004; 19: 671-8.
31. Yamamoto T, Umegae S, Kitagawa T, Yasuda Y, Yamada Y, Takahashi D, Mukumoto
M, Nishimura N, Yasue K, Matsumoto K. Granulocyte and monocyte adsorptive
apheresis in the treatment of active distal ulcerative colitis: A prospective, pilot study.
Aliment Pharmacol Ther 2004; 20: 783-92.
32. Yamamoto T, Umegae S, Kitagawa T, Matsumoto K. Postoperative change of mucosal
inflammation at strictureplasty segment in Crohn’s disease: Cytokine production andendoscopic and histologic findings. Dis Colon Rectum 2005; 48: 749-57.
33. Yamamoto T, Umegae S, Kitagawa T, Matsumoto K. Intraperitoneal cytokine
productions and their relationship to peritoneal sepsis and systemic inflammatory
markers in patients with inflammatory bowel disease. Dis Colon Rectum 2005; 48:1005-15.
34. Yamamoto T, Umegae S, Kitagawa T, Matsumoto K. The value of plasma cytokine
measurement for the detection of strangulation in patients with bowel obstruction: A
prospective, pilot study. Dis Colon Rectum 2005; 48: 1451-9.
35. Yamamoto T. Factors affecting recurrence after surgery for Crohn’s disease. World J
Gastroenterol 2005; 11: 3971-9.
36. Yamamoto T, Nakahigashi M, Umegae S, Kitagawa T, Matsumoto K. Impact ofelemental diet on mucosal inflammation in patients with active Crohn’s disease:
Cytokine production and endoscopic and histological findings. Inflamm Bowel Dis
2005; 11: 580-8.
37. Keh C, Shatari T, Yamamoto T, Menon A, Clark MA, Keighley MR. Jejunal Crohn’sdisease is associated with a higher post-operative recurrence rate than ileocecal
Crohn’s disease. Colorectal Dis 2005; 7: 366-8.
38. Yamamoto T, Umegae S, Kitagawa T, Matsumoto K. Systemic and local cytokine
production in quiescent ulcerative colitis and its relationship to future relapse: A
prospective, pilot study. Inflamm Bowel Dis 2005; 11: 589-96.
39. Yamamoto T, Umegae S, Kitagawa T, Matsumoto K. The impact of the fecal stream
and stasis on immunologic reactions in ileal pouch after restorative proctocolectomy
for ulcerative colitis: A prospective, pilot study. Am J Gastroenterol 2005; 100:
2248-53.
40. Yamamoto T, Umegae S, Matsumoto K. Safety and clinical efficacy of granulocyte

and monocyte adsorptive apheresis therapy for ulcerative colitis. World J
Gastroenterol 2006; 12: 520-5.
41. Yamamoto T, Nakahigashi M, Umegae S, Kitagawa T, Matsumoto K. Acute duodenal
Crohn’s disease successfully managed with low-speed elemental diet infusion via
nasogastric tube: A case report. World J Gastroenterol 2006; 12: 649-51.
42. Yamamoto T, Saniabadi AR, Umegae S, Matsumoto K. Impact of selective
leukocytapheresis on mucosal inflammation and ulcerative colitis: Cytokine profiles
and endoscopic findings. Inflamm Bowel Dis 2006; 12: 719-26.
43. Kosaka T, Yoshino J, Inui K, Wakabayashi T, Okushima K, Kobayashi T, Miyoshi H,
Nakamura Y, Hayashi S, Shiraishi T, Watanabe M, Yamamoto T, Nakahara A, Katoh
T. Impact of lipoprotein lipase gene polymorphisms on ulcerative colitis. World J
Gastroenterol 2006; 12: 6325-30.
44. Reese GE, Lovegrove RE, Tilney HS, Yamamoto T, Heriot AG, Fazio VW, Tekkis
PP. The effect of Crohn’s disease on outcomes after restorative proctocolectomy. Dis
Colon Rectum 2007; 50: 239-50.
45. Reese GE, Purkayastha S, Tilney HS, von Roon A, Yamamoto T, Tekkis PP.
Strictureplasty vs resection in small bowel Crohn’s disease: an evaluation ofshort-term outcomes and recurrence. Colorectal Dis 2007; 9: 686-94.
46. Yamamoto T, Nakahigashi M, Umegae S, Kitagawa T, Matsumoto K. Impact oflong-term enteral nutrition on clinical and endoscopic recurrence after resection for
Crohn’s disease: A prospective, non-randomized, parallel, controlled study. Aliment
Pharmacol Ther 2007; 25: 67-72.
47. Yamamoto T, Fazio VW, Tekkis PP. Safety and efficacy of strictureplasty for Crohn’sdisease: A systematic review and meta-analysis. Dis Colon Rectum 2007; 50:
1968-86.
48. Iwata T, Yamamoto T, Umegae S, Matsumoto K. Pouchitis and pre-pouch ileitis
developed after restorative proctocolectomy for ulcerative colitis: A case report.
World J Gastroenterol 2007; 13: 643-6.
49. Simillis C, Purkayastha S, Yamamoto T, Strong SA, Darzi AW, Tekkis PP. A
meta-analysis comparing conventional end-to-end anastomosis vs. other anastomotic
configurations after resection in Crohn’s disease. Dis Colon Rectum 2007; 50:
1674-87.
50. Yamamoto T. The current status of strictureplasty for Crohn’s disease. Curr Med Lit
Gastroenterol 2007; 26: 57-65.
51. Yamamoto T, Saniabadi AR, Maruyama Y, Umegae S, Matsumoto K. Factors
affecting clinical and endoscopic efficacies of selective leucocytapheresis forulcerative colitis. Dig Liver Dis 2007; 39: 626-33.
52. Yamamoto T, Nakahigashi M, Saniabadi AR, Iwata T, Maruyama Y, Umegae S,
Matsumoto K. Impacts of long-term enteral nutrition on clinical and endoscopic
disease activities and mucosal cytokines during remission in patients with Crohn’sdisease: A prospective study. Inflamm Bowel Dis 2007; 13: 1493-501.
53. Simillis C, Yamamoto T, Reese GE, Umegae S, Matsumoto K, Darzi AW, Tekkis PP.
A meta-analysis comparing incidence of recurrence and indication for reoperation
after surgery for perforating versus nonperforating Crohn’s disease. Am J
Gastroenterol 2008; 103: 196-205.
54. Yamamoto T, Maruyama Y, Umegae S, Matsumoto K, Saniabadi A. Mucosal
inflammation in the terminal ileum of ulcerative colitis patients: Endoscopic findings
and cytokine profiles. Dig Liver Dis 2008; 40: 253-9.
55. Reese GE, Nanidis T, Borysiewicz C, Yamamoto T, Orchard T, Tekkis PP. The effectof smoking after surgery for Crohn’s disease: a meta-analysis of observational studies.
Int J Colorectal Dis 2008; 23: 1213-21.
56. Yamamoto T, Umegae S, Matsumoto K. Impact of infliximab therapy after earlyendoscopic recurrence following ileocolonic resection of Crohn’s disease: A
prospective pilot study. Inflamm Bowel Dis 2009; 15: 1460-6.
57. Yamamoto T, Nakahigashi M, Saniabadi AR. Review article: diet and inflammatory
bowel disease - epidemiology and treatment. Aliment Pharmacol Ther 2009; 30:
99-112.
58. Kosaka T, Yoshino J, Inui K, Wakabayashi T, Kobayashi T, Watanabe S, Hayashi S,
Hirokawa Y, Shiraishi T, Yamamoto T, Tsuji M, Katoh T, Watanabe M. Involvementof NAD(P)H: Quinone oxidoreductase 1 and superoxide dismutase polymorphisms inulcerative colitis. DNA Cell Biol 2009; 28: 625-31.
59. Yamamoto T, Nakahigashi M, Umegae S, Matsumoto K. Enteral nutrition formaintenance of remission in Crohn’s disease: A systematic review. Eur J
Gastroenterol Hepatol 2010; 22: 1-8.
60. Yamamoto T, Nakahigashi M, Umegae S, Matsumoto K. Prospective clinical trial:
Enteral nutrition during maintenance infliximab in Crohn’s disease. J Gastroenterol
2010; 45: 24-9.
61. Simillis C, Jacovides M, Reese GE, Yamamoto T, Tekkis PP. Meta-analysis of therole of granulomas in the recurrence of Crohn disease. Dis Colon Rectum 2010; 53:
177-85.
62. Yamamoto T, Umegae S, Matsumoto K. Mucosal healing in patients with ulcerative
colitis during a course of selective leukocytapheresis therapy: A prospective cohort

study. Inflamm Bowel Dis 2010; 16: 1905-11.
63. Augestad KM, Lindsetmo RO, Stulberg J, Reynolds H, Senagore A, Champagne B,
Heriot AG, Leblanc F, Delaney CP; International Rectal Cancer Study Group(IRCSG). International preoperative rectal cancer management: staging, neoadjuvant
treatment, and impact of multidisciplinary teams. World J Surg 2010; 34: 2689-700.
64. Yamamoto T. Prevention of recurrence after surgery for Crohn’s disease: Efficacy ofinfliximab. World J Gastroenterol 2010; 16: 5405-10.
65. Yamamoto T. Granulocyte and monocyte adsorptive apheresis in the management ofulcerative colitis. Aliment Pharmacol Ther 2011; 33: 288.
66. Yamamoto T, Umegae S, Matsumoto K, Saniabadi AR. Peritoneal cytokines as earlymarkers of peritonitis following surgery for colorectal carcinoma: A prospective study.
Cytokine 2011; 53: 239-42.
67. Yamamoto T, Umegae S, Matsumoto K. High-dose mesalazine treatment for
ulcerative colitis patients who relapse under low-dose maintenance therapy. Dig Liver
Dis 2011; 43: 386-90.
68. Yamamoto T, Nakahigashi M, Saniabadi AR. Dietary interventions in patients with
inflammatory bowel disease. Practical Gastroenterology 2011; 35: 10-26.
69. Yamamoto T, Umegae S, Matsumoto K. Daily granulocyte and monocyte adsorptive
apheresis in patients with active ulcerative colitis: A prospective safety and feasibility
study. J Gastroenterol 2011; 46: 1003-9.
70. Nakahigashi M, Yamamoto T. Increases in body mass index during infliximab therapy
in patients with Crohn’s disease: An open label prospective study. Cytokine 2011; 56:
531-5.
71. Yamamoto T, Umegae S, Matsumoto K. Long-term clinical impact of early
introduction of granulocyte and monocyte adsorptive apheresis in new onset,
moderately active, extensive ulcerative colitis. J Crohns Colitis 2012; 6: 750-5.
72. Shiraki M, Yamamoto T. Steroid-sparing strategies in the management of ulcerative
colitis: Efficacy of leukocytapheresis. World J Gastroenterol 2012; 18: 5833-8.
73. Yamamoto T, Shiraki M, Nakahigashi M, Umegae S, Matsumoto K. Enteral nutrition
to suppress postoperative Crohn’s disease recurrence: A five-year prospective cohort
study. Int J Colorectal Dis 2013; 28: 335-40.
74. Yamamoto T. Nutrition and diet in inflammatory bowel disease. Curr Opin
Gastroenterol 2013; 29: 216-21.
75. Yamamoto T, Watanabe T. Strategies for the prevention of postoperative recurrence of
Crohn’s disease. Colorectal Dis 2013; 15: 1471-80.
76. Bamba T, Sohma S, Yamamoto T. The risk of postoperative complications following

preoperative anti-TNF therapy in patients with Crohn’s disease: The need forprospective studies. J Crohns Colitis 2013; 7: e493-4.
77. Yamamoto T, Bamba T, Umegae S, Matsumoto K. The impact of early endoscopic
lesions on the clinical course of patients following ileocolonic resection for Crohn’sdisease: a 5-year prospective cohort study. United European Gastroenterology Journal
2013; 1: 294-8.
78. Yamamoto T, Shiraki M, Bamba T, Umegae S, Matsumoto K. Faecal calprotectin andlactoferrin as markers for monitoring disease activity and predicting clinicalrecurrence in patients with Crohn’s disease after ileocolonic resection: a prospective
pilot study. United European Gastroenterology Journal 2013; 1: 368-74.
79. Bamba T, Yamamoto T, Umegae S, Matsumoto K. Effects of preoperative
leukocytapheresis on inflammatory cytokines following surgery for ulcerative colitis:
A prospective randomized study. J Clin Apheresis 2014; 29: 107-12.
80. Matsuda S, Bamba T, Sohma S, Yamamoto T. Postoperative infliximab and elemental
diet combination in a case with diffuse, extensive jejunoileal Crohn’s disease. Int J
Colorectal Dis 2014; 29: 265-6.
81. Yamamoto T, Watanabe T. Surgery for luminal Crohn’s disease. World J
Gastroenterol 2014; 20: 78-90.
82. Yamamoto T, Shiraki M, Bamba T, Umegae S, Matsumoto K. Fecal calprotectin andlactoferrin as predictors of relapse in patients with quiescent ulcerative colitis during
maintenance therapy. Int J Colorectal Dis 2014; 29: 485-91.
83. Saniabadi AR, Tanaka T, Ohmori T, Sawada K, Yamamoto T, Hanai H. Treating
inflammatory bowel disease by adsorptive leucocytapheresis: A desire to treat without
drugs. World J Gastroenterol 2014; 20: 9699-715.
84. Yamamoto T. Diagnosis and monitoring of postoperative recurrence in Crohn’sdisease. Expert Rev Gastroenterol Hepatol 2015; 9: 55-66.
85. Sacco R, Tanaka T, Yamamoto T, Bresci G, Saniabadi AR. Adacolumn
leucocytapheresis for ulcerative colitis: clinical and endoscopic features of responders
and unresponders. Expert Rev Gastroenterol Hepatol 2015; 9: 327-33.
86. Yamamoto T. The clinical value of faecal calprotectin and lactoferrin measurement inpostoperative Crohn’s disease. United European Gastroenterol J 2015; 3: 5-10.
87. Kotze PG, Yamamoto T, Danese S, Suzuki Y, Teixeira FV, de Albuquerque IC,
Saad-Hossne R, de Barcelos IF, da Silva RN, Kotze LM, Olandoski M, Sacchi M,
Yamada A, Takeuchi K, Spinelli A. Direct retrospective comparison of adalimumab
and infliximab in preventing early postoperative endoscopic recurrence after
ileocaecal resection for Crohn’s disease: results from the MULTIPER database. J

Crohns Colitis 2015; 9: 541-7.
88. Yamamoto T, Shimoyama T, Bamba T, Matsumoto K. Consecutive monitoring of
fecal calprotectin and lactoferrin for the early diagnosis and prediction of pouchitis
after restorative proctocolectomy for ulcerative colitis. Am J Gastroenterol 2015; 110:881-7.
89. Yamamoto T, Shimoyama T. Can fecal biomarkers detect ileal inflammation in
inflammatory bowel disease ? Am J Gastroenterol 2015; 110:1370.
90. Kotze PG, Spinelli A, da Silva RN, de Barcelos IF, Teixeira FV, Saad-Hossne R, deAlbuquerque IC, Olandoski M, da Silva Kotze LM, Suzuki Y, Yamada A, Takeuchi
K, Sacchi M, Yamamoto T. Conventional versus biological therapy for prevention of
postoperative endoscopic recurrence in patients with Crohn’s disease: an international,
multicenter, and observational study. Intest Res 2015; 13: 259-65.
91. Yamamoto T, Shimoyama T, Matsumoto K. Consecutive monitoring of faecal
calprotectin during mesalazine suppository therapy for active rectal inflammation inulcerative colitis. Aliment Pharmacol Ther 2015; 42: 549-58.
92. Yoshimura N, Yokoyama Y, Matsuoka K, Takahashi H, Iwakiri R, Yamamoto T,
Nakagawa T, Fukuchi T, Motoya S, Kunisaki R, Kato S, Hirai F, Ishiguro Y, Tanida S,
Hiraoka S, Mitsuyama K, Ishihara S, Tanaka S, Otaka M, Osada T, Kagaya T, Suzuki
Y, Nakase H, Hanai H, Watanabe K, Kashiwagi N, Hibi T. An open-label prospective
randomized multicenter study of intensive versus weekly granulocyte and monocyte
apheresis in active crohn’s disease. BMC Gastroenterol 2015; 15: 163.
93. Nakahigashi M, Yamamoto T, Sacco R, Hanai H, Kobayashi F. Enteral nutrition formaintaining remission in patients with quiescent Crohn’s disease: current status andfuture perspectives. Int J Colorectal Dis 2016; 31: 1-7.
94. Sugimoto K, Ikeya K, Iida T, Kawasaki S, Arai O, Umehara K, Watanabe F, Tani S,
Oishi S, Osawa S, Yamamoto T, Hanai H. An increased serum N-Terminal
Telopeptide of Type I Collagen, a biochemical marker of increased bone resorption, isassociated with infliximab therapy in patients with Crohn’s disease. Dig Dis Sci 2016;
61: 99-106.
95. Yamamoto T, Spinelli A, Suzuki Y, Saad-Hossne R, Teixeira FV, de Albuquerque IC,
da Silva RN, de Barcelos IF, Takeuchi K, Yamada A, Shimoyama T, da Silva Kotze
LM, Sacchi M, Danese S, Kotze PG. Risk factors for complications after ileocolonicresection for Crohn’s disease with a major focus on the impact of preoperative
immunosuppressive and biologic therapy: A retrospective international multicentre
study. United European Gastroenterol J 2016; 4: 784-93.
96. Yamamoto T, Shimoyama T, Umegae S, Matsumoto K. Tacrolimus vs. anti-tumournecrosis factor agents for moderately to severely active ulcerative colitis: aretrospective observational study. Aliment Pharmacol Ther 2016; 43: 705-16.
97. Yamamoto T, Shimoyama T, Umegae S, Matsumoto K. Editorial: tacrolimus vs.
anti-tumour necrosis factor agents for moderately to severely active ulcerative colitis authors’ reply. Aliment Pharmacol Ther 2016; 43: 1017-8.
98. Okuyama Y, Doi Y, Matsuyama N, Uchino M, Yamamoto T. A novel sol particle
immunoassay for fecal calprotectin in inflammatory bowel disease patients. Clin
Chim Acta 2016; 456: 1-6.
99. Yamamoto T, Shimoyama T, Umegae S, Matsumoto K. Serial monitoring of faecal
calprotectin for the assessment of endoscopic recurrence in asymptomatic patients
after ileocolonic resection for Crohn’s disease: a long-term prospective study. Therap
Adv Gastroenterol 2016; 9: 664-70.
100. Yamamoto T, Shimoyama T, Kuriyama M. Letter: faecal calprotectin for theprediction of relapse in inactive inflammatory bowel disease. Aliment Pharmacol Ther
2016; 44: 769-70.
101. Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, Blank MA,
Johanns J, Gao LL, Miao Y, Adedokun OJ, Sands BE, Hanauer SB, Vermeire S,
Targan S, Ghosh S, de Villiers WJ, Colombel JF, Tulassay Z, Seidler U, Salzberg BA,
Desreumaux P, Lee SD, Loftus EV Jr, Dieleman LA, Katz S, Rutgeerts P; UNITI–
IM-UNITI Study Group. Ustekinumab as induction and maintenance therapy for
Crohn’s disease. N Engl J Med 2016; 375: 1946-60.
102. Yamamoto T, Tanaka T, Yokoyama T, Shimoyama T, Ikeuchi H, Uchino M, Watanabe
T. Efficacy of granulocyte and monocyte apheresis for antibiotic-refractory pouchitis
after proctocolectomy for ulcerative colitis: An open-label, prospective, multicentre
study. Therap Adv Gastroenterol 2017; 10: 199-206.
103. de Barcelos IF, Kotze PG, Spinelli A, Suzuki Y, Teixeira FV, de Albuquerque IC,
Saad-Hossne R, da Silva Kotze LM, Yamamoto T. Factors affecting the incidence ofearly endoscopic recurrence after ileocolonic resection for Crohn’s disease: amulticentre observational study. Colorectal Dis 2017; 19: O39-O45.
104. Yamamoto T, Shimoyama T, Kuriyama M. Dietary and enteral interventions for
Crohn’s disease. Curr Opin Biotech 2017; 44: 69-73.
105. 2015 European Society of Coloproctology collaborating group. The relationshipbetween method of anastomosis and anastomotic failure after right hemicolectomy
and ileo-caecal resection: an international snapshot audit. Colorectal Dis 2017; 19:e296-e311.
106. Nagahori M, Kochi S, Hanai H, Yamamoto T, Nakamura S, Omuro S, Watanabe M,

Hibi T; OPTIMUM Study Group. Real life results in using 5-ASA for maintaining
mild to moderate UC patients in Japan, a multi-center study, OPTIMUM Study. BMC
Gastroenterol 2017; 17: 47.
107. Shimoyama T, Yamamoto T, Umegae S, Matsumoto K. Faecal biomarkers forscreening small bowel inflammation in patients with Crohn’s disease: A prospective
study. Therap Adv Gastroenterol 2017; 10: 577-87.
108. Tanaka T, Yamamoto T, Sawada K, Sacco R. Treatment options for children andadolescents with inflammatory bowel disease: is granulomonocytapheresis aneffective alternative to drug therapy? Expert Rev Gastroenterol Hepatol 2017; 11:749-58.
109. Yamamoto T, Shimoyama T. Monitoring and detection of disease recurrence after
resection for Crohn’s disease: the role of non-invasive fecal biomarkers. Expert Rev
Gastroenterol Hepatol 2017; 11: 899-909.
110. Kotze PG, Magro DO, Martinez CAR, Saab B, Saab MP, Pinheiro LV, Olandoski M,
Yamamoto T, Coy CSR. Adalimumab and postoperative complications of elective
intestinal resections in Crohn’s disease: a propensity score case-matched study.
Colorectal Dis 2018; 20: 211-8.
111. 2015 European Society of Coloproctology collaborating group. Risk factors forunfavourable postoperative outcome in patients with Crohn’s disease undergoing righthemicolectomy or ileocaecal resection An international audit by ESCP and S-ECCO.
Colorectal Dis 2018; 20: 219-27.
112. Takeuchi K, Shimoyama T, Yamamoto T. Comparison of safety and efficacy oftacrolimus versus infliximab for active ulcerative colitis. Dig Dis 2018；36：106-12.
113. Naganuma M, Sugimoto S, Mitsuyama K, Kobayashi T, Yoshimura N, Ohi H, Tanaka
S, Andoh A, Ohmiya N, Saigusa K, Yamamoto T, Morohoshi Y, Ichikawa H,
Matsuoka K, Hisamatsu T, Watanabe K, Mizuno S, Suda W, Hattori M, Fukuda S,
Hirayama A, Abe T, Watanabe M, Hibi T, Suzuki Y, Kanai T; INDIGO Study Group.
Efficacy of Indigo naturalis in a multicenter randomized controlled trial of patientswith ulcerative colitis. Gastroenterology 2018; 154: 935-47.
114. Kotze PG, Shen B, Lightner A, Yamamoto T, Spinelli A, Ghosh S, Panaccione R.
Modern management of perianal fistulas in Crohn’s disease: Future directions. Gut
2018; 67: 1181-94.
115. Yamamoto T, Shimoyama T, Umegae S, Matsumoto K. Endoscopic score vs. fecal
biomarkers for predicting relapse in patients with ulcerative colitis after clinicalremission and mucosal healing. Clin Transl Gastroenterol 2018; 9: 136.
116. Kondo S, Araki T, Okita Y, Yamamoto A, Hamada Y, Katsurahara M, Horiki N,

Nakamura M, Shimoyama T, Yamamoto T, Takei Y, Kusunoki M. Colitis with wall
thickening and edematous changes during oral administration of the powdered form of
Qing-dai in patients with ulcerative colitis: a report of two cases. Clin J Gastroenterol
2018; 11: 268-72.
117. Kotze PG, Yamamoto T, Damião AO. Postoperative approach for Crohn’s disease:
the right therapy to the right patient. Curr Drug Targets 2018; 19: 729-39.
118. Kotze PG, Magro DO, Martinez CAR, Spinelli A, Yamamoto T, Warusavitarne J,
Coy CSR. Long time from diagnosis to surgery may increase postoperativecomplication rates in elective cd intestinal resections: an observational study.
Gastroenterol Res Pract. 2018; 2018: 4703281.
119. Yamamoto T, Iida T, Ikeya K, Kato M, Matsuura A, Tamura S, Takano R, Tani S,
Osawa S, Sugimoto K, Shimoyama T, Hanai H. A multicenter retrospective study
aiming to identify patients who respond well to adsorptive granulomonocytapheresis
in moderately to severely active ulcerative colitis. Clin Transl Gastroenterol 2018; 9:170.
120. Tham YS, Yung DE, Fay S, Yamamoto T, Ben-Horin S, Eliakim R, Koulaouzidis A,
Kopylov U. Fecal calprotectin for detection of postoperative endoscopic recurrence in
Crohn’s disease: systematic review and meta-analysis. Therap Adv Gastroenterol
2018; 11: 1756284818785571.
121. Yamamoto T, Kotze PG, Spinelli A, Panaccione R. Fistula-associated anal carcinoma
in Crohn’s disease. Expert Rev Gastroenterol Hepatol 2018; 12: 917-25.
122. Shimoyama T, Yamamoto T, Umegae S, Matsumoto K. Faecal calprotectin level forassessing endoscopic activity and predicting future clinical course in patients withmoderately active ulcerative colitis undergoing granulomonocytapheresis: aprospective cohort study. BMC Gastroenterol 2018; 18: 120.
123. 2015 European Society of Coloproctology Collaborating Group. The impact ofstapling technique and surgeon specialism on anastomotic failure after right-sided
colorectal resection: an international multicentre, prospective audit. Colorectal Dis
2018; 20: 1028-40.
124. Yamamoto T, Kotze PG. Letter: can a specific surgical approach reduce post-operative
recurrence in Crohn’s disease? Aliment Pharmacol Ther 2018; 48: 1030-31.
125. Saniabadi AR, Tanaka T, Yamamoto T, Kruis W, Sacco R. Granulomonocytapheresis
as a cell-dependent treatment option for patients with inflammatory bowel disease:
Concepts and clinical features for better therapeutic outcomes. J Clin Apheresis 2019;34: 51-60.
126. Yamamoto T, Shimoyama T, Umegae S, Kotze PG. Impact of preoperative nutritional

status on the incidence rate of surgical complications in patients with inflammatory
bowel disease with vs without preoperative biologic therapy: A case-control study.
Clinical and Translational Gastroenterology 2019; 10: e00050.
127. Argollo M, Kotze PG, Lamonaca L, Gilardi D, Furfaro F, Yamamoto T, Danese S.
Prevention of postoperative recurrence in Crohn’s disease: tailoring treatment topatient profile. Curr Drug Targets 2019; 20: 1327-38.
128. Yamamoto T, Teixeira FV, Saad-Hossne R, Kotze PG, Danese S. Anti-TNF andpostoperative complications in abdominal Crohn’s disease surgery. Curr Drug Targets
2019; 20: 1339-48.
129. Naganuma M, Sugimoto S, Suzuki H, Matsuno Y, Araki T, Shimizu H, Hayashi R,
Fukuda T, Nakamoto N, Iijima H, Nakamura S, Kataoka M, Tamura Y, Tatsumi K,
Hibi T, Suzuki Y, Kanai T; INDIGO survey Group. Adverse events in patients withulcerative colitis treated with indigo naturalis: a Japanese nationwide survey. J
Gastroenterol 2019; 54: 891-6.
130. Uchino M, Ikeuchi H, Hata K, Okada S, Ishihara S, Morimoto K, Sahara R, Watanabe
K, Fukushima K, Takahashi K, Kimura H, Hirata K, Mizushima T, Araki T, Kusunoki
M, Nezu R, Nakao S, Itabashi M, Hirata A, Ozawa H, Ishida T, Okabayashi K,
Yamamoto T, Noake T, Arakaki J, Watadani Y, Ohge H, Futatsuki R, Koganei K,
Sugita A, Higashi D, Futami K. Changes in the rate of and trends in colectomy forulcerative colitis during the era of biologics and calcineurin inhibitors based on a
Japanese nationwide cohort study. Surg Today 2019; 49: 1066-73.
131. Carvello M, Lightner A, Yamamoto T, Kotze PG, Spinelli A. Mesenchymal stem cells
for perianal Crohn’s disease. Cells 2019; 8: 764.
132. Naganuma M, Sugimoto S, Fukuda T, Mitsuyama K, Kobayashi T, Yoshimura N, Ohi
H, Tanaka S, Andoh A, Ohmiya N, Saigusa K, Yamamoto T, Morohoshi Y, Ichikawa
H, Matsuoka K, Hisamatsu T, Watanabe K, Mizuno S, Abe T, Suzuki Y, Kanai T;
INDIGO Study Group. Indigo naturalis is effective even in treatment-refractorypatients with ulcerative colitis: a post hoc analysis from the INDIGO study. J
Gastroenterol. 2019; 55: 169-80.
133. 2015 European Society of Coloproctology (ESCP) collaborating group. Patients with
Crohn’s disease have longer post-operative in-hospital stay than patients with coloncancer but no difference in complications' rate. World J Gastrointest Surg 2019; 11:261-70.
134. Yamamoto T, Nakahigashi M, Shimoyama T, Umegae S. Does preoperative enteralnutrition reduce the incidence of surgical complications in patients with Crohn’sdisease? A case-matched study. Colorectal Dis 2020 [Epub ahead of print].

135. Motoya S, Tanaka H, Shibuya T, Osada T, Yamamoto T, Hongo H, Mizuno C, Saito
D, Aoyama N, Kobayashi T, Ito H, Tanida S, Nojima M, Kokuma S, Hosoi E. Safety
and effectiveness of granulocyte and monocyte adsorptive apheresis in patients with
inflammatory bowel disease in special situations: a multicentre cohort study. BMC
Gastroenterol 2019; 19: 196.
136. Naganuma M, Yokoyama Y, Motoya S, Watanabe K, Sawada K, Hirai F, Yamamoto T,
Hanai H, Omori T, Kanai T, Hibi T; CAPTAIN study Group. Efficacy of apheresis as
maintenance therapy for patients with ulcerative colitis in an open-label prospective
multicenter randomised controlled trial. J Gastroenterol [Epub ahead of print].
137. Yamamoto T, Carvello M, Lightner AL, Spinelli A, Kotze PG. Up-to-date surgery forulcerative colitis in the era of biologics. Expert Opin Biol Ther 2020; 20: 391-8.
邦文論文
1. 山本隆行, 田中光司, 松本好市. 小児クローン病の長期予後. 小児外科 2000; 32:
76-80.
2. 大北喜基, 山本隆行, 梅枝 覚, 松本好市. 水腎症を合併したCrohn病の1例. 日本臨床外科学会雑誌 2004; 65(6): 1583-7.
3. 山本隆行. 難治性潰瘍性大腸炎に対する新しい治療. 三重医報 学術 2007 年 9月号 第 562 号 pp38-9.
4. 小坂俊二, 芳野純治, 乾 和郎, 若林貴夫, 奥嶋一武, 小林 隆, 三好広尚, 渡邉真也, 服部昌志, 林 繁和, 白石泰三, 山本隆行, 渡邉昌俊, 中澤三郎. 潰瘍性大腸炎と DNA メチル化との関連 －one-carbon metabolism 関連遺伝子多型を中心に－. 消化器医学 2009; 7: 74-80.
5. 山本隆行. クローン病術後早期の内視鏡病変に対するインフリキシマブの有効性:
前向き臨床試験. INTESTINE 2009; 13: 654-6.
6. 山本隆行. 主題 「Crohn病小腸病変に対する治療効果」 栄養療法の粘膜治癒効
果. 胃と腸 2010; 45: 1621-9.
7. 山本隆行. 特集 I 「炎症性腸疾患の病態に基づいた治療法の開発」 クローン病
術後早期の内視鏡病変に対するインフリキシマブの有効性. 消化器内科 2010; 51:
373-8.
8. 梅枝 覚, 松本好市, 北川達士, 野地みどり, 山本隆行, 石井雅昭, 肥満智紀,
山崎 学. 人工肛門造設および皮膚縫合に対する埋没縫合のこころみ. 東海ストー
マ・排泄リハビリテーション研究会誌 2010; 30(1): 49-54.
9. 山本隆行. 潰瘍性大腸炎患者における白血球除去療法の粘膜治癒効果: 前向き
コホート試験. INTESTINE 2011; 15(4): 383-5.
10. 梅枝 覚, 松本好市, 北川達士, 野地みどり, 山本隆行, 石井雅昭, 成田 清, 鳥

井孝宏, 肥満智紀, 山崎 学. 肛門悪性リンパ腫の 1 例. 日本大腸肛門病学会雑誌
2011; 64(5): 332-6.
11. 山本隆行. クローン病の治療戦略－治療の基本と効果向上のための方策 経腸栄養療法. 消化器の臨床 2011; 14 (6): 582-6.
12. 山本隆行, 中東真紀. 各論 エビデンスに基づく病態別経腸栄養療法～病態別経
腸栄養剤の選び方と使い方～: 炎症性腸疾患 クローン病治療における経腸栄養の現状と今後の展望: 本邦と欧米の比較. 静脈経腸栄養 2012; 27 (2): 657-64.
13. 山本隆行. 特集 炎症性腸疾患のすべて 新しい治療戦略 クローン病の外科治療
開腹手術. 臨床外科 2012; 67(10): 1258-63.
14. 山本隆行. 手術手技 クローン病の腸管切除と術後再発予防のストラテジー. 手術
2012; 66(13): 1897-901.
15. 山本隆行. 特集：クローン病手術のすべて 大腸クローン病の病変部位や範囲を考慮した術式選択とその治療成績. 手術 2013; 67(9): 1271-6.
16. 白木 学, 山本隆行, 梅枝 覚, 松本好市. CT enterography 後カプセル内視鏡を施行しえたクローン病 4 症例の検討. 三重医報 2013 年 7 月 1 日発行 第 632 号
pp44-46.
17. 梅枝 覚, 松本好市, 山本隆行, 中山茂樹, 石井雅昭, 肥満智紀. 初回手術後, 6回の再発切除術を繰り返し, 25 年間にわたり経過観察されている直腸原発 GIST の
1 例. 手術 2013; 67(10): 1557-63.
18. 山本隆行. 炎症性腸疾患(IBD)に対する生物学的製剤治療：生物学的製剤への切り替え, 他の治療法との併用をどう行うか. 消化器の臨床 2013; 16(5): 479-82.
19. 山本隆行. 炎症性腸疾患の最新治療－栄養療法のエビデンスを中心に. 臨床栄
養 2013; 123(7): 849-55.
20. 山本隆行. 重症型･劇症型潰瘍性大腸炎による緊急治療や緊急治療時の対応. 消化器最新看護 2013; 18(5): 42-9.
21. 梅枝 覚, 山本隆行, 松本好市, 中山茂樹, 湯沢浩之, 肥満智紀. Crohn 病による
肛門狭窄部に発生した肛門管癌の 1 例. 日本臨床外科学会雑誌 2014; 75(1):158-63.
22. 山本隆行. 特集 ここまで来た, 炎症性腸疾患の新展開 Crohn 病の外科治療－近年の変化. 成人病と生活習慣病 2014; 44(3): 327-30.
23. 山本隆行, 白木 学, 松本好市. 難治性潰瘍性大腸炎に対する顆粒球除去療法の集中治療: 連続 5 日法の安全性と有効. 消化器内科 2014; 58(6): 739-43.
24. 山本隆行. ERAS 時代の周術期管理マニュアル III. 術式別の術前・術中・術後管理 3. 小腸・大腸 小腸切除術. 臨床外科 2014; 69(11): 124-6.
25. 山本隆行. テーマ：炎症性腸疾患外科治療の最近の動向 2. Crohn 病治療の最近の動向. 日外会誌 2015; 116(2): 82-6.

26. 山本隆行, 下山貴寛. 特集：潰瘍性大腸炎の最適治療と臨床的問題への対策 血球成分吸着除去療法をどう行うか－その導入のタイミング. 消化器の臨床 2015;
18(4)351-6.
27. 長太のどか, 中東真紀, 石原領子, 山本隆行. 炎症性腸疾患に対する BIA 法による In Body 測定を用いた栄養学的評価の有用性. 日本病態栄養学会誌 2015;18(3): 347-53.
28. 山本隆行, 下山貴寛, 名和俊平. 術後障害のリアル―外来フォローの実力が臓器損失を補う 評価・対応の実際 小腸 吸収不良症候群, 短腸症候群. 臨床外科
2016; 71(3): 305-9.
29. 山本隆行, 下山貴寛, 後藤信二, 栗山萌子. 特集/IBDの妊娠と周産期をめぐる疑問に答える! IBD合併妊娠と手術. IBD Research 2016; 10(3): 164-9.
30. 山本隆行. 次世代の自己免疫疾患診療に向けて IBD 領域 UC 治療における抗TNF 製剤の使用意義. クリニシアン 2016; 63(10): 1027-33.
31. 梅枝 覚, 中山茂樹, 山本隆行, 肥満智紀, 鈴木桜子. 生活習慣と痔疾患. 成人
病と生活習慣病 2016; 46(12): 1481-7.
32. 山本隆行, 下山貴寛. 特集 炎症性腸疾患の手術治療を極める 結腸亜全摘・回腸
人工肛門造設・S 状結腸粘液瘻造設術. 手術 2017; 71(2): 121-6.
33. 山本隆行, 下山貴寛, 前田聡, 宇都宮志織. 炎症性腸疾患 －最近の診断・治療－ III. 炎症性腸疾患の治療 栄養・食事療法. 日本臨牀 2017; 75(3): 414-8.
34. 山本隆行, 下山貴寛, 梅枝 覚. 主題 I. 炎症性腸疾患診療の最前線. Crohn 病腸管病変に対する外科的治療の最前線: 多職種連携チームによる周術期管理. 日本
大腸肛門病学会雑誌 2017; 70(10): 611-22.
35. 山本隆行, 下山貴寛, 中東真紀. 病棟栄養士のためのベーシックセミナー: 経腸栄養編. 3. 疾患・病態別の栄養療法. 炎症性腸疾患に対する経腸栄養. 臨床栄養
2017; 131(4): 516-24.
36. 下山貴寛, 山本隆行, 井上靖浩, 梅枝 覚. 手術にて救命し得た DIC 合併難治性
潰瘍性大腸炎の 1 例. 手術 2017; 71(12): 1683-90.
37. 山本隆行. クローン病術後管理の Treat to Target (T2T). クリニシアン 2018; 65:
933-9.
38. 梅枝 覚, 中山茂樹, 木村充志, 井上靖浩, 山本隆行, 下山貴寛, 肥満智紀, 鈴
木桜子, 北川達士. 裂肛の治療. 消化器外科 2018; 41: 1163-73.
39. 石原領子, 中東真紀, 長太のどか, 山本隆行. 炎症性腸疾患に対する栄養経過指標としての上腕周囲長および下腿周囲長の有用性. 日本病態栄養学会誌 2018;
21: 347-63.
40. 梅枝 覚, 中山茂樹, 木村充志, 井上靖浩, 山本隆行, 下山貴寛. 難治性肛門疾
患の手術治療. 手術 2018; 72: 1319-24.

41. 梅枝 覚, 山本隆行, 中山茂樹, 木村充志, 井上靖浩, 下山貴寛, 濱口哲也, 肥満智紀, 鈴木桜子, 北川達士. 痔核の治療 —結紮切除術を見直そう. 外科 2018;
80: 1306-1312.
42. 山本隆行, 下山貴寛. モニタリング: カルプロテクチンと一般検査. 診断と治療
2019; 107: 783-8.
43. 山本隆行, 下山貴寛, 梅枝 覚. 炎症性腸疾患の内科治療 血球成分除去療法.
臨牀消化器内科 2019; 34: 167-72.
44. 下山貴寛, 山本隆行, 井上靖浩, 梅枝 覚. 潰瘍性大腸炎類似胃十二指腸炎を発症した大腸全摘術後潰瘍性大腸炎の 2 例. 日臨外会誌 2019; 80(5): 904-12.
英文著書
1. Yamamoto T.
Crohn’s disease: Aetiology, pathology, diagnosis and medical treatment.
Surgery of the Anus, Rectum & Colon, The 3rd Edition.
Editors: Michael RB Keighley and Norman S Williams.
Saunders Elsevier.
2. Yamamoto T.
Surgery for intestinal Crohn’s disease and postoperative management for preventionof recurrence: Current evidence.
Crohn’s Disease: Etiology, Pathogenesis and Interventions, 2008 4th Quarter
Editor: Jack N Cadwallader.
Nova Publishers.
3. Yamamoto T.
The Handbook of Nutrition, Diet and Sleep
Enteral support at sleep time in Crohn’s disease
Editor: Professor Victor R Preedy, Dr Vinood Patel and Dr Lan Le
Wageningen Academic Publishers.
4. Yamamoto T.
Management of isolated proctitis/proctosigmoiditis. Mastery of IBD Surgery.
Springer.
邦文著書
1. 山本隆行. 医学文献 ユーザーズガイド. 根拠に基づく診療のマニュアル 第 2 版
監訳: 相原守夫, 池田正行, 三原華子, 村山隆之. 凸版メディア株式会社
2. 山本隆行, 梅枝 覚, 松本好市. 消化器病学の進歩－原点から未来への情報発信. 緩解期クローン病に対する長期経腸栄養療法の臨床的および内視鏡効果: 前向き比較試験. 第 94 回日本消化器病学会総会記念誌 I. 消化管領域 2009;241-3.
3. 山本隆行. 炎症性腸疾患の外科治療: Surgical strategy for Inflammatory Bowel
Disease V クローン病 手術手技の実際 腸管切除と腸管吻合. 佐々木 巌, 杉田昭, 二見喜太郎 編集. メディカルビュー社 pp132-138, 2013
4. 山本 隆行, 渡邉 聡明. 大腸疾患 Now 2014. Biological Era におけるクローン病の外科治療の現状と今後の課題. 杉原健一 編集顧問 藤盛孝博, 五十嵐正広, 渡
邉聡明 編集. 武藤徹一郎 編集顧問. 日本メディカルセンター pp131-136, 2014
5. 山本 隆行. エビデンスに基づいた診療. 現場のエキスパートが教える 実践! IBD
診療. 渡辺 守, 久松理一, 渡辺憲治 編集. 医学出版 pp 96-97, 2014
6. 山本 隆行. クローン病 潰瘍性大腸炎. ナースのための入門書. 消化器の画像がわかる. 監修: 片山和宏. 編著: 石原 立, 伊藤敏文, 大川和良, 瀬田剛史, 内藤
雅文, 中西克之, 山本克己, 山本隆行. 日総研 pp56-59, 2016
7. 山本 隆行. 消化器医のための重要論文 240 篇 炎症性腸疾患編. 株式会社シービーアール pp230, 239, 245, 250, 2019
国際学会報告1. Yamamoto T, Connolly AB, Allan RN, Morton DG, Keighley MRB. It is not possible
to predict which patients with Crohn’s disease will respond to faecal diversion alone.
United European Gastroenterology Week. October, 18-23 1997, Birmingham, UK.
2. Yamamoto T, Connolly AB, Allan RN, Morton DG, Keighley MRB. Strictureplasty is
not associated a higher recurrence than repeat resection after ileo-colonic resection for
Crohn’s disease. United European Gastroenterology Week. October, 18-23 1997,
Birmingham, UK.
3. Yamamoto T, Connolly AB, Allan RN, Morton DG, Keighley MRB. Duodenal
Crohn’s disease is associated with high morbidity and conventional surgical treatment
may not always relieve obstruction. United European Gastroenterology Week.
October, 18-23 1997, Birmingham, UK.
4. Yamamoto T, Bain IM, Allan RN, Keighley MRB. Comparisons of strictureplasty andrepeated resection for ileocolonic recurrence in Crohn’s disease. British Society of
Gastroenterology, Spring Meeting. March 10-13, 1998, Harrogate, UK.
5. Yamamoto T, Bain IM, Allan RN, Keighley MRB. Side-to-side stapled versus
end-to-end sutured anastomosis following ileocolonic resection for Crohn’s disease.
British Society of Gastroenterology, Spring Meeting. March 10-13, 1998, Harrogate,
UK.
6. Yamamoto T, Bain IM, Allan RN, Keighley MRB. Risk factors for anastomotic

recurrence after ileocolonic resection for Crohn’s disease: the importance of smoking.
British Society of Gastroenterology, Spring Meeting. March 10-13, 1998, Harrogate,
UK.
7. Yamamoto T, Bain IM, Allan RN, Keighley MRB. Gastroduodenal Crohn’s disease:the clinical features and management. British Society of Gastroenterology, Spring
Meeting. March 10-13, 1998, Harrogate, UK.
8. Yamamoto T, Bain IM, Allan RN, Keighley MRB. Perforating Crohn’s disease does
not carry a high risk of recurrence but usually represents as perforating disease. The
American Society of Colon & Rectal Surgeons Annual Meeting. May 2-7, 1998, San
Antonio, Texas, U.S.A.
9. Yamamoto T, Bain IM, Allan RN, Keighley MRB. Perineal wound healing after
proctectomy for Crohn’s disease. The American Society of Colon & Rectal Surgeons
Annual Meeting. May 2-7, 1998, San Antonio, Texas, U.S.A.
10. Yamamoto T, Bain IM, Allan RN, Keighley MRB. An audit of strictureplasty for
Crohn’s disease. The American Society of Colon & Rectal Surgeons Annual Meeting.
May 2-7, 1998, San Antonio, Texas, U.S.A.
11. Yamamoto T, Bain IM, Allan RN, Keighley MRB. The efficacy of faecal diversion
alone for extensive Crohn’s disease. Association of Surgeons of Great Britain and
Ireland, Annual Scientific Meeting. May 13-15, 1998, Edinburgh, UK.
12. Yamamoto T, Bain IM, Allan RN, Keighley MRB. Risk factors for anastomotic
recurrence after ileocolonic resection for Crohn’s disease. Association of Surgeons ofGreat Britain and Ireland, Annual Scientific Meeting. May 13-15, 1998, Edinburgh,UK.
13. Yamamoto T, Bain IM, Allan RN, Keighley MRB. The outcome of surgical treatmentsfor perineal sinus after proctectomy for Crohn’s disease. Association of Surgeons ofGreat Britain and Ireland, Annual Scientific Meeting. May 13-15, 1998, Edinburgh,UK.
14. Yamamoto T, Bain IM, Allan RN, Keighley MRB. Comparisons of stapled andsutured anastomosis following ileocolonic resection for Crohn’s disease. Associationof Surgeons of Great Britain and Ireland, Annual Scientific Meeting. May 13-15,
1998, Edinburgh, UK.
15. Yamamoto T, Bain IM, Allan RN, Keighley MRB. Risk factors for anastomotic
recurrence after ileocolonic resection for Crohn’s disease: the importance of smoking.
Digestive Disease Week, American Gastroenterological Association. May 17-20,
1998, New Orleans, Louisiana, U.S.A.
16. Yamamoto T, Bain IM, Allan RN, Keighley MRB. Side-to-side stapled versus

end-to-end sutured anastomosis following ileocolonic resection for Crohn’s disease:
complications and early recurrence rates. Digestive Disease Week, American
Gastroenterological Association. May 17-20, 1998, New Orleans, Louisiana, U.S.A.
17. Yamamoto T, Bain IM, Allan RN, Keighley MRB. The outcome of surgical treatmentsfor perineal sinus after proctectomy for Crohn’s disease. International Society of
University Colon and Rectal Surgeons, XVIIth Biennial Congress. June 7-11, 1998,
Malmö, Sweden.
18. Yamamoto T, Bain IM, Allan RN, Keighley MRB. The efficacy of faecal diversion
alone for extensive Crohn’s disease. International Society of University Colon andRectal Surgeons, XVIIth Biennial Congress. June 7-11, 1998, Malmö, Sweden.
19. Yamamoto T, Bain IM, Allan RN, Keighley MRB. Risk factors for anastomotic
recurrence after ileocolonic resection for Crohn’s disease: the importance of smoking.
International Society of University Colon and Rectal Surgeons, XVIIth Biennial
Congress. June 7-11, 1998, Malmö, Sweden.
20. Yamamoto T, Bain IM, Allan RN, Keighley MRB. Comparisons of strictureplasty andrepeated resection for ileocolonic recurrence in Crohn’s disease. International Societyof University Colon and Rectal Surgeons, XVIIth Biennial Congress. June 7-11, 1998,
Malmö, Sweden.
21. Yamamoto T, Bain IM, Allan RN, Keighley MRB. Gastroduodenal fistulas in Crohn’sdisease: clinical features and management. International Society of University Colonand Rectal Surgeons, XVIIth Biennial Congress. June 7-11, 1998, Malmö, Sweden.
22. Yamamoto T, Bain IM, Allan RN, Keighley MRB. Role of surgery for obstructing
gastroduodenal Crohn’s disease: strictureplasty gives disappointing results.
International Society of University Colon and Rectal Surgeons, XVIIth Biennial
Congress. June 7-11, 1998, Malmö, Sweden.
23. Yamamoto T, Bain IM, Allan RN, Keighley MRB. Side-to-side stapled versus
end-to-end sutured anastomosis following ileocolonic resection for Crohn’s disease.
International Society of University Colon and Rectal Surgeons, XVIIth Biennial
Congress. June 7-11, 1998, Malmö, Sweden.
24. Yamamoto T, Bain IM, Allan RN, Keighley MRB. The long-term results ofproctocolectomy for Crohn’s disease. The Association of Coloproctology of GreatBritain and Ireland, Annual Meeting. June 29 - July 1, 1998, Jersey, UK.
25. Yamamoto T, Bain IM, Allan RN, Keighley MRB. Side-to-side stapled versus
end-to-end sutured anastomosis following ileocolonic resection for Crohn’s disease:
complications and early recurrence rates. The Association of Coloproctology of GreatBritain and Ireland, Annual Meeting. June 29 - July 1, 1998, Jersey, UK.

26. Yamamoto T, Bain IM, Allan RN, Keighley MRB. The outcome of strictureplasty forshort ileocolonic anastomotic recurrence in Crohn’s disease. The Association of
Coloproctology of Great Britain and Ireland, Annual Meeting. June 29 - July 1, 1998,
Jersey, UK.
27. Yamamoto T, Bain IM, Allan RN, Keighley MRB. The outcome of strictureplasty for
jejunoileal Crohn’s disease. The Association of Coloproctology of Great Britain and
Ireland, Annual Meeting. June 29 - July 1, 1998, Jersey, UK.
28. Yamamoto T, Bain IM, Allan RN, Keighley MRB. Gastroduodenal fistulas in Crohn’sdisease: clinical features and management. The Association of Coloproctology ofGreat Britain and Ireland, Annual Meeting. June 29 - July 1, 1998, Jersey, UK.
29. Yamamoto T, Bain IM, Allan RN, Keighley MRB. Risk factors for anastomotic
recurrence after ileocolic resection for Crohn’s disease: the importance of smoking.
The Association of Coloproctology of Great Britain and Ireland, Annual Meeting.
June 29 - July 1, 1998, Jersey, UK.
30. Yamamoto T, Keighley MRB. The long-term results of proctocolectomy for Crohn’sdisease. 16th World Congress Collegium Internationale Chirurgiae Digestivae(CICD). September 16-19, 1998, Madrid, Spain.
31. Yamamoto T, Bain IM, Keighley MRB. Side-to-side stapled versus end-to-end sutured
anastomosis following ileocolonic resection for Crohn’s disease. 16th World Congress
Collegium Internationale Chirurgiae Digestivae (CICD). September 16-19, 1998,
Madrid, Spain.
32. Yamamoto T, Bain IM, Keighley MRB. Risk factors for anastomotic recurrence after
ileocolonic resection for Crohn’s disease. 16th World Congress CollegiumInternationale Chirurgiae Digestivae (CICD). September 16-19, 1998, Madrid, Spain.
33. Yamamoto T, Bain IM, Keighley MRB. The outcome of strictureplasty for small
bowel Crohn’s disease. 16th World Congress Collegium Internationale Chirurgiae
Digestivae (CICD). September 16-19, 1998, Madrid, Spain.
34. Yamamoto T, Allan RN, Keighley MRB. Role of surgery for obstructing
gastroduodenal Crohn’s disease: strictureplasty gives disappointing results. 2nd
International Inflammatory Bowel Disease Meeting, November, 22-24 1998, Chester,UK.
35. Yamamoto T, Allan RN, Keighley MRB. The long-term results of proctocolectomy for
Crohn’s disease. 2nd International Inflammatory Bowel Disease Meeting, November,
22-24 1998, Chester, UK.
36. Yamamoto T, Allan RN, Keighley MRB. The outcome of strictureplasty for small
bowel Crohn’s disease. 2nd International Inflammatory Bowel Disease Meeting,November, 22-24 1998, Chester, UK.
37. Yamamoto T, Allan RN, Keighley MRB. Stapled functional end-to-end anastomosis
versus sutured end-to-end anastomosis following ileocolonic resection in Crohn’sdisease. 2nd International Inflammatory Bowel Disease Meeting, November, 22-24
1998, Chester, UK.
38. Yamamoto T, Boulton RA, Bain IM, Allan RN, Keighley MRB.
Risk factors for anastomotic recurrence after ileocolonic resection for Crohn’s disease.
2nd International Inflammatory Bowel Disease Meeting, November, 22-24 1998,
Chester, UK.
39. Yamamoto T, Allan RN, Keighley MRB. Faecal diversion alone in the management ofanorectal Crohn’s disease. European Society of Surgery, 2nd Annual Meeting.
December 3-5, 1998, London, UK.
40. Yamamoto T, Boulton RA, Bain IM, Allan RN, Keighley MRB. Risk factors foranastomotic recurrence after ileocolonic resection for Crohn’s disease: the importanceof smoking. European Society of Surgery, 2nd Annual Meeting. December 3-5, 1998,
London, UK.
41. Yamamoto T, Allan RN, Keighley MRB. The outcome of strictureplasty for
jejunoileal Crohn’s disease. European Society of Surgery, 2nd Annual Meeting.
December 3-5, 1998, London, UK.
42. Yamamoto T, Allan RN, Keighley MRB. The long-term results of proctocolectomy
for Crohn’s disease. European Society of Surgery, 2nd Annual Meeting. December
3-5, 1998, London, UK.
43. Yamamoto T, Allan RN, Keighley MRB. Stapled functional end-to-end anastomosis
versus sutured end-to-end anastomosis following ileocolonic resection in Crohn’sdisease. European Society of Surgery, 2nd Annual Meeting. December 3-5, 1998,
London, UK.
44. Yamamoto T, Allan RN, Keighley MRB. The outcome of strictureplasty for duodenal
Crohn’s disease. European Society of Surgery, 2nd Annual Meeting. December 3-5,
1998, London, UK.
45. Yamamoto T, Allan RN, Keighley MRB. An audit of single-stage proctocolectomy for
Crohn’s disease: postoperative complications and recurrence. British Society of
Gastroenterology Meeting. March 23-25, 1999, Glasgow, UK.
46. Yamamoto T, Allan RN, Keighley MRB. Only smoking is a predictive factor foroutcome after colectomy and ileorectal anastomosis in Crohn’s colitis. British Societyof Gastroenterology Meeting. March 23-25, 1999, Glasgow, UK.
47. Yamamoto T, Allan RN, Keighley MRB. A strategy for the surgical management of

ileocolonic anastomotic recurrence in Crohn’s disease. British Society of
Gastroenterology Meeting. March 23-25, 1999, Glasgow, UK.
48. Yamamoto T, Keighley MRB. Faecal diversion alone in the management of anorectal
Crohn’s disease. The American Society of Colon & Rectal Surgeons, 100th
Anniversary and Tripartite Meeting. May 2-7, 1999, Washington DC, U.S.A.
49. Yamamoto T, Keighley MRB. Only smoking is a predictive factor for outcome after
colectomy and ileorectal anastomosis in Crohn’s colitis. The American Society ofColon & Rectal Surgeons, 100th Anniversary and Tripartite Meeting. May 2-7, 1999,
Washington DC, U.S.A.
50. Yamamoto T, Allan RN, Keighley MRB. Risk factors for anastomotic dehiscence andintra-abdominal sepsis after surgery in Crohn’s disease. The American Society ofColon & Rectal Surgeons, 100th Anniversary and Tripartite Meeting. May 2-7, 1999,
Washington DC, U.S.A.
51. Yamamoto T, Allan RN, Keighley MRB. The outcome of strictureplasty for duodenal
Crohn’s disease. Association of Surgeons of Great Britain and Ireland, Annual
Scientific Meeting, May 4-7, 1999, Brighton, UK.
52. Yamamoto T, Allan RN, Keighley MRB. The fate of the rectum and ileal recurrence
rates after total colectomy for Crohn’s disease. Association of Surgeons of GreatBritain and Ireland, Annual Scientific Meeting, May 4-7, 1999, Brighton, UK.
53. Yamamoto T, Allan RN, Keighley MRB. Surgical management of ileocolonicanastomotic recurrence in Crohn’s disease Association of Coloproctology of GreatBritain and Ireland, Annual Meeting, June 9-11, 1999, Southport, UK.
54. Yamamoto T, Allan RN, Keighley MRB. Long-term outcome of total colectomy andileostomy for Crohn’s disease. Association of Coloproctology of Great Britain and
Ireland, Annual Meeting, June 9-11, 1999, Southport, UK.
55. Yamamoto T, Allan RN, Keighley MRB. The outcome of strictureplasty for duodenal
Crohn’s disease. Association of Coloproctology of Great Britain and Ireland, Annual
Meeting, June 9-11, 1999, Southport, UK.
56. Yamamoto T. Symposium: Controversies in inflammatory bowel disease: part II
Crohn’s colitis and perineum. 38th World Congress of Surgery of the ISS/SIC,
International Surgical Week ISW 99. August 15-20, 1999, Vienna, Austria.
57. Yamamoto T. Symposium: Controversies in inflammatory bowel disease: part I
Duodenal Crohn’s disease. 38th World Congress of Surgery of the ISS/SIC,
International Surgical Week ISW 99. August 15-20, 1999, Vienna, Austria.
58. Yamamoto T, Allan RN, Keighley MRB. The efficacy of faecal diversion alone forextensive Crohn’s disease. The 7th Congress of Asian Federation of Coloproctology.

November 5-8, 1999, Beijing, China.
59. Yamamoto T, Allan RN, Keighley MRB. Gastroduodenal fistulas in Crohn’s disease:clinical features and management. The 7th Congress of Asian Federation of
Coloproctology. November 5-8, 1999, Beijing, China.
60. Yamamoto T, Allan RN, Keighley MRB. Risk factors for anastomotic recurrence after
ileocolonic resection for Crohn’s disease. The 7th Congress of Asian Federation of
Coloproctology. November 5-8, 1999, Beijing, China.
61. Yamamoto T, Allan RN, Keighley MRB. Side-to-side stapled versus end-to-end
sutured anastomosis following ileocolonic resection for Crohn’s disease. The 7th
Congress of Asian Federation of Coloproctology. November 5-8, 1999, Beijing,
China.
62. Yamamoto T, Allan RN, Keighley MRB. The outcome of strictureplasty for small
bowel Crohn’s disease. The 7th Congress of Asian Federation of Coloproctology.
November 5-8, 1999, Beijing, China.
63. Yamamoto T, Allan RN, Keighley MRB. The long-term results of proctocolectomy for
Crohn’s disease. The 7th Congress of Asian Federation of Coloproctology. November
5-8, 1999, Beijing, China.
64. Yamamoto T, Allan RN, Keighley MRB. Only smoking is a predictive factor foroutcome after colectomy and ileorectal anastomosis in Crohn’s colitis. The 7th
Congress of Asian Federation of Coloproctology. November 5-8, 1999, Beijing,
China.
65. Yamamoto T, Allan RN, Keighley MRB. The outcome of strictureplasty for duodenal
Crohn’s disease. The 7th Congress of Asian Federation of Coloproctology. November
5-8, 1999, Beijing, China.
66. Yamamoto T, Allan RN, Keighley MRB. The fate of the rectum and ileal recurrence
rates after total colectomy for Crohn’s disease. The 7th Congress of Asian Federationof Coloproctology. November 5-8, 1999, Beijing, China.
67. Yamamoto T, Allan RN, Keighley MRB. Long-term outcome of total colectomy andileostomy for Crohn’s disease. The 7th Congress of Asian Federation of
Coloproctology. November 5-8, 1999, Beijing, China.
68. Yamamoto T, Allan RN, Keighley MRB. Surgical management of ileocolonicanastomotic recurrence in Crohn’s disease. The 7th Congress of Asian Federation of
Coloproctology. November 5-8, 1999, Beijing, China.
69. Yamamoto T, Allan RN, Keighley MRB. Multiple operations in patients with Crohn’sdisease. The American Society of Colon & Rectal Surgeons Annual Meeting. June
24-29, 2000, Boston, USA.

70. Yamamoto T, Allan RN, Keighley MRB. The impact of disease location on clinicalcourse in patients with Crohn’s disease. The American Society of Colon & Rectal
Surgeons Annual Meeting. June 24-29, 2000, Boston, USA.
71. Yamamoto T, Allan RN, Keighley MRB. Stoma construction in patients with Crohn’sdisease. The American Society of Colon & Rectal Surgeons Annual Meeting. June
24-29, 2000, Boston, USA.
72. Ryan W, Yamamoto T, Keighley M. Patients who stop smoking have a reduced risk ofrecurrent Crohn’s disease. The American Society of Colon & Rectal Surgeons Annual
Meeting. June 2-7, 2001, San Diego, USA.
73. Yamamoto T, Allan RN, Keighley MRB. Results of strictureplasty for diffuse
jejunoileal Crohn’s disease. DDW-Japan 2000 English Session 5, Kobe. October
25-28, 2000.
74. Yamamoto T, Umegae S, Kitagawa T, Matsumoto K. Systemic and local cytokine
productions during remission after bowel resection and their relationship to future
relapse in patients with Crohn’s disease. XXth Biennial Congress of the International
Society of University Colon and Rectal Surgeons. June 6-10, 2004, Budapest,
Hungary.
75. Yamamoto T, Umegae S, Kitagawa T, Matsumoto K. Systemic and local cytokine
profiles in patients with active Crohn’s disease and their relationship to diseaseactivity and clinical presentation. XXth Biennial Congress of the International Societyof University Colon and Rectal Surgeons. June 6-10, 2004, Budapest, Hungary.
76. Yamamoto T, Umegae S, Kitagawa T, Matsumoto K. The impact of enteral nutrition
on cytokine production in ileal mucosa after resection for Crohn’s disease. XXthBiennial Congress of the International Society of University Colon and Rectal
Surgeons. June 6-10, 2004, Budapest, Hungary.
77. Yamamoto T, Umegae S, Kitagawa T, Matsumoto K. Increased cytokine production in
macroscopically normal colonic mucosa from patients with Crohn’s disease. 19th
World Congress of International Society for Digestive Surgery. December 8-11, 2004,
Yokohama, Japan.
78. Yamamoto T, Umegae S, Kitagawa T, Matsumoto K. Systemic and local cytokine
productions in quiescent ulcerative colitis and their relationship to future relapse. 19th
World Congress of International Society for Digestive Surgery. December 8-11, 2004,
Yokohama, Japan.
79. Yamamoto T, Umegae S, Kitagawa T, Matsumoto K. Risk factors for future relapse
after bowel resection in patients with Crohn’s disease. 10th Congress of AsianFederation of Coloproctology. March 24-26, 2005, Singapore.

80. Yamamoto T, Umegae S, Kitagawa T, Matsumoto K. The impact of elemental diet on
clinical disease activity and systemic and mucosal inflammation in patients with
Crohn’s disease. 10th Congress of Asian Federation of Coloproctology. March 24-26,
2005, Singapore.
81. Yamamoto T, Umegae S, Kitagawa T, Matsumoto K. Granulocyte and monocyte
adsorptive apheresis therapy for mild to moderate active distal ulcerative colitis. 10th
Congress of Asian Federation of Coloproctology. March 24-26, 2005, Singapore.
82. Yamamoto T, Umegae S, Kitagawa T, Matsumoto T. Systemic and local cytokine
production in quiescent ulcerative colitis and its relationship to future relapse: A
prospective, pilot study. Japan-Korea IBD Symposium. September 23, 2006, Seoul,
Korea.
83. Yamamoto T, Nakahigashi M, Umegae S, Kitagawa T, Matsumoto T. Impact ofelemental diet on mucosal inflammation in patients with active Crohn’s disease:
Cytokine production and endoscopic and histological findings. Japan-Korea IBD
Symposium. September 23, 2006, Seoul, Korea.
84. Yamamoto T, Umegae S, Kitagawa T, Matsumoto T. Postoperative change of
mucosal cytokine production at strictureplasty sites in Crohn’s disease. International
Society for Digestive Surgery. November 29-December 2, 2006, Rome, Italy.
85. Yamamoto T, Umegae S, Kitagawa T, Matsumoto T. Plasma and mucosal cytokine
production during remission after resection for Crohn’s disease and its relationship to
future relapse. International Society for Digestive Surgery. November 29-December 2,
2006, Rome, Italy.
86. Yamamoto T, Umegae S, Kitagawa T, Matsumoto T. Risk factors for disease
recurrence after surgery for Crohn’s disease: A review. International Society for
Digestive Surgery. November 29-December 2, 2006, Rome, Italy.
87. Yamamoto T, Umegae S, Kitagawa T, Matsumoto T. Effects of preoperative
adsorptive leukocytapheresis on immunologic reactions and septic complications after
restorative proctocolectomy for active ulcerative colitis: A prospective study. The
American Society of Colon and Rectal Surgeons Annual Meeting. June 2-6, 2007, St.
Louis, U.S.A.
88. Maruyama Y, Yamamoto T, Iwata T, Umegae S, Matsumoto K. Clinicopathologicaland immunological findings of pouchitis and prepouch ileitis developed after
restorative proctocolectomy for ulcerative colitis: A case report. The 11th Congress ofAsian Federation of Coloproctology. September 20-22, 2007, Tokyo, Japan.
89. Maruyama Y, Yamamoto T, Iwata T, Umegae S, Matsumoto K, Saniabadi AR. Safety
and efficacies of selective leukocytapheresis for moderately or severely active

ulcerative colitis. The 11th Congress of Asian Federation of Coloproctology.
September 20-22, 2007, Tokyo, Japan.
90. Keighley M, Yamamoyo T, Perakath B, Sen I. Emerging (Indian) Crohn’s disease
presents at an older age and predominantly in the jejuna-ileum compared withestablished (UK) disease. The Second Annual Meeting of the European Society ofColoproctology. September 26-29, 2007, Portomaso, Malta.
91. Yamamoto T, Kim BS, Parikh R, Strong SA, Moench J, Pallotta SL, Manilich E,
Fazio VW. Intestinal carcinoma in Crohn’s disease: Clinicopathological features andsurgical outcome. The American Society of Colon and Rectal Surgeons Annual
Meeting. June 7-12, 2008, Boston, U.S.A.
92. Nakahigashi M, Yamamoto T. The effects of long-term enteral nutrition on nutritional
status in patients with crohn’s disease: a prospective comparative study. 15th
International Congress of Dietetics (ICD). September 8-11, 2008, Yokohama.
93. Yamamoto T. Invited lecture: Crohn’s disease of the colon including anorectal
disease. Colorectal Congress. December 5, 2008, St. Gallen, Switzerland.
94. Simillis C, Yamamoto T, Reese G, Umegae S, Matsumoto K, Darzi A, Tekkis P. A
meta-analysis comparing the incidence of recurrence and indication for reoperation
after surgery for perforating versus non-perforating Crohn’s disease. The Fourth
Annual Meeting of the European Society of Coloproctology. September 23-26, 2009,
Prague, Czech Republic.
95. Simillis C, Michael J, Reese G, Yamamoto T, Tekkis P. The role of granulomas in therecurrence of Crohn’s disease - a meta-analysis. The Fourth Annual Meeting of theEuropean Society of Coloproctology.September 23-26, 2009, Prague, Czech Republic.
96. Yamamoto T, Umegae S, Matsumoto K, Saniabadi AR. The relationship between
endoscopic findings at the proximal site of anastomosis and subsequent relapse
following ileal/ileocolonic resection for Crohn’s disease: A prospective endoscopic
cohort study. United European Gastroenterology Week for 2009 (GASTRO 2009).
November 23, 2009, London, UK.
97. Yamamoto T, Nakahigashi M, Umegae S, Matsumoto K, Saniabadi AR. Concomitantenteral nutrition therapy during maintenance infliximab in patients with Crohn’sdisease: A prospective trial. United European Gastroenterology Week for 2009(GASTRO 2009). November 23, 2009, London, UK.
98. Yamamoto T, Nakahigashi M, Umegae S, Matsumoto K, Saniabadi AR. The efficacy
of enteral nutrition in the management of patients with Crohn’s disease in remission:clinical outcomes of two prospective studies. United European Gastroenterology
Week for 2009 (GASTRO 2009). November 23, 2009, London, UK.

99. Yamamoto T, Umegae S, Matsumoto K. The relationship between endoscopic
findings at the proximal site of anastomosis and subsequent clinical relapse following
ileal/ileocolonic resection for Crohn’s disease: a prospective endoscopic cohort study.
The 4th Korea-Japan IBD Symposium. January 23, 2010, Tokyo, Japan.
100. Yamamoto T, Umegae S, Matsumoto K. Concomitant enteral nutrition therapy during
maintenance infliximab in patients with Crohn’s disease: a prospective trial. The 4th
Korea-Japan IBD Symposium. January 23, 2010, Tokyo, Japan.
101. Yamamoto T, Umegae S, Matsumoto K. The efficacy of infliximab for earlyendoscopic recurrence after resection of Crohn’s disease: a prospective pilot study.
The 4th Korea-Japan IBD Symposium. January 23, 2010, Tokyo, Japan.
102. Yamamoto T, Umegae S, Matsumoto K. High-dose, 4.0 g/day mesalamine for patientswith ulcerative colitis who relapsed under low-dose, 1.5-2.25 g/day maintenancetherapy: safety and efficacy. United European Gastroenterology Week for 2010
(GASTRO 2010). October 27, 2010, Barcelona, Spain.
103. Yamamoto T, Umegae S, Matsumoto K. Mucosal healing in patients with ulcerative
colitis during a course of granulocyte/monocyte adsorption therapy: a prospective
cohort study. United European Gastroenterology Week for 2010 (GASTRO 2010).
October 27, 2010, Barcelona, Spain.
104. Yamamoto T, Nakahigashi M, Umegae S, Matsumoto K, Saniabadi AR. The efficacy
of enteral nutrition in the management of patients with Crohn’s disease in remission.
United European Gastroenterology Week for 2010 (GASTRO 2010). October 27,
2010, Barcelona, Spain.
105. Yamamoto T. Symposium: Does the Adacolumn therapy induce mucosal healing?
October 26, 2010, Barcelona, Spain.
106. Yamamoto T, Umegae S, Matsumoto K. Systemic and peritoneal inflammatory
response after laparoscopic or conventional restorative proctocolectomy in patientswith ulcerative colitis. United European Gastroenterology Week for 2011 (GASTRO
2011). October 24, 2011, Stockholm, Sweden.
107. Yamamoto T, Umegae S, Matsumoto K. Safety and feasibility of daily granulocyte
and monocyte adsorptive apheresis in patients with active ulcerative colitis: A
prospective study. United European Gastroenterology Week for 2011 (GASTRO
2011). October 24, 2011, Stockholm, Sweden.
108. Yamamoto T, Umegae S, Matsumoto K Mucosal healing in patients with active
ulcerative colitis during granulocyte and monocyte apheresis therapy: a prospective
cohort study. The 6th Korea-Japan Inflammatory Bowel Disease Symposium. January
28, 2012, Tokyo, Japan.

109. Yamamoto T, Umegae S, Matsumoto K Safety and feasibility of daily granulocyte andmonocyte apheresis in patients with active ulcerative colitis: a prospective study. The
6th Korea-Japan Inflammatory Bowel Disease Symposium. January 28, 2012, Tokyo,
Japan.
110. Yamamoto T, Umegae S, Matsumoto K Safety and efficacy of high-dose, 4.0 g/day
mesalazine therapy for patients with ulcerative colitis who relapsed under low-dose,
1.5-2.25 g/day maintenance therapy: a prospective study. The 6th Korea-Japan
Inflammatory Bowel Disease Symposium. January 28, 2012, Tokyo, Japan.
111. Shiraki M, Yamamoto T, Umegae S, Matsumoto K. Long-term clinical impact of early
introduction of leukocytapheresis in patients with new onset ulcerative colitis. United
European Gastroenterology Week for 2012 (GASTRO 2012). October 22, 2012,
Amsterdam, Netherlands.
112. Shiraki M, Yamamoto T, Umegae S, Matsumoto K. Enteral nutrition to suppress
postoperative Crohn’s disease recurrence: a five-year prospective cohort study. United
European Gastroenterology Week for 2012 (GASTRO 2012). October 22, 2012,
Amsterdam, Netherlands.
113. Shiraki M, Yamamoto T, Umegae S, Matsumoto K Impacts of infliximab therapy on
nutritional status in patients with Crohn’s disease: a prospective study. United
European Gastroenterology Week for 2012 (GASTRO 2012). October 23, 2012,
Amsterdam, Netherlands.
114. Yamamoto T, Shiraki M, Umegae S, Matsumoto K. The usefulness of peritoneal
cytokines as early predictors of peritonitis following surgery for colorectal carcinoma:a prospective study. United European Gastroenterology Week for 2012 (GASTRO
2012). October 23, 2012, Amsterdam, Netherlands.
115. Yamamoto T, Shiraki M, Umegae S, Matsumoto K. A prospective randomized study
to investigate the effects of preoperative adsorptive leukocytapheresis on
inflammatory cytokines and septicemia after restorative proctocolectomy forulcerative colitis. United European Gastroenterology Week for 2012 (GASTRO
2012). October 23, 2012, Amsterdam, Netherlands.
116. Yamamoto T, Shiraki M, Umegae S, Matsumoto K. Long-term clinical impact of early
introduction of granulocyte and monocyte adsorptive apheresis in new onset
ulcerative colitis. 8th Congress of ECCO - Inflammatory Bowel Diseases 2013.
Vienna, Austria. February 15, 2013.
117. Yamamoto T, Shiraki M, Umegae S, Matsumoto K. The effect of infliximab therapy
on nutritional status in patients with Crohn’s disease. 8th Congress of ECCO Inflammatory Bowel Diseases 2013. Vienna, Austria. February 15, 2013.

118. Yamamoto T, Shiraki M, Umegae S, Matsumoto K. The long-term efficacy of enteralnutrition for the prevention of postoperative recurrence in Crohn’s disease: A five-year
prospective cohort study. 8th Congress of ECCO - Inflammatory Bowel Diseases
2013. Vienna, Austria. February 15, 2013.
119. Yamamoto T, Shiraki M, Umegae S, Matsumoto K. Impacts of elemental diet therapy
on clinical disease activity and nutritional status in patients with quiescent Crohn’sdisease. 15th Parenteral and Enteral Nutrition Society of Asia (PENSA) Congress.
Kuta Bali, Indonesia. September 27-29, 2013.
120. Yamamoto T, Shiraki M, Umegae S, Matsumoto K. Faecal calprotection andlactoferrin are relevant markers for monitoring disease activity and predicting
recurrence in patients with quiescent Crohn’s disease following ileocolonic resection.
United European Gastroenterology Week for 2013 (GASTRO 2013).
Berlin, Germany. October 14, 2013.
121. Yamamoto T, Shiraki M, Umegae S, Matsumoto K. The impact of early endoscopic
lesions on the clinical course of patients after ileocolonic resection for Crohn’sdisease: a five-year prospective cohort study. United European Gastroenterology
Week for 2013 (GASTRO 2013). Berlin, Germany.
122. Yamamoto T, Kotze P, Suzuki Y, Spinelli A, Danese S, Saad-Hossne R, Teixeira F,
Albuquerque I, Silva R, Barcelos I, Yamada A, Kotze L, Sacchi M. The risk of
postoperative complications following preoperative immunosuppressive therapy inpatients undergoing ileocolonic resection for Crohn’s disease. 9th Congress of ECCO
- Inflammatory Bowel Diseases 2014. Copenhagen, Denmark. February 21, 2014.
123. Yamamoto T, Shiraki M, Umegae S, Matsumoto K. Fecal calprotectin and lactoferrin
as predictors of relapse in patients with quiescent ulcerative colitis during
maintenance therapy. 9th Congress of ECCO - Inflammatory Bowel Diseases 2014.
Copenhagen, Denmark. February 21, 2014.
124. Kotze PG, Suzuki Y, Yamamoto T, Danese S, Saad-Hossne R, Teixeira F, AlbuquerqueI, Silva R, Barcelos I, Yamada A, Kotze L, Sacchi M, Olandoski M, Spinelli A. Direct
retrospective comparison of Adalimumab and Infliximab in preventing early
postoperative endoscopic recurrence after ileocecal resection for Crohn’s disease:results from the MULTIPER database. 9th Congress of ECCO - Inflammatory Bowel
Diseases 2014. Copenhagen, Denmark. February 21, 2014.
125. Suzuki Y, Kotze PG, Spinelli A, Saad-Hossne R, Yamada A, Sacchi M, Teixeira F,
Albuquerque I, Barcelos I, Silva R, Kotze L, Olandoski M, Danese S, Yamamoto T.
Retrospective comparison of the efficacy of anti-TNF agents in isolation or combinedwith azathioprine in prevention of early postoperative endoscopic recurrence inCrohn’s disease from the MULTIPER database. 9th Congress of ECCO Inflammatory Bowel Diseases 2014. Copenhagen, Denmark. February 21, 2014.
126. Kotze PG, Yamamoto T, Danese S, Suzuki Y, Albuquerque I, Barcelos I, Kotze L,
Olandoski M, Teixeira F, Silva R, Sacchi M, Yamada A, Saad-Hossne R, Spinelli A.
Does the location of an IBD centre impact the rates of early postoperative endoscopic
recurrence after ileocecal resection in Crohn’s disease? Results from the MULTIPER
database. 9th Congress of ECCO - Inflammatory Bowel Diseases 2014. Copenhagen,Denmark. February 21, 2014.
127. Kotze PG, Suzuki Y, Yamamoto T, Danese S, Saad-Hossne R, Albuquerque IC,
Teixeira FV, Silva RN, Barcelos IF, Olandoski M, Kotze LM, Yamada A, Spinelli A.
Direct retrospective comparison of Adalimumab and Infliximab in preventing early
postoperative endoscopic recurrence after ileocecal resection for Crohn’s disease:results from the MULTIPER database. Digestive Disease Week (DDW) 2014.
Chicago, USA. May 4, 2014.
128. Suzuki Y, Kotze PG, Spinelli A, Saad-Hossne R, Yamada A, Sacchi M, Teixeira FV,
Albuquerque IC, Barcelos IF, Silva RN, Kotze LM, Olandoski M, Danese S,
Yamamoto T. Retrospective comparison of the efficacy of anti-TNF agents in isolationor combined with azathioprine in prevention of early postoperative endoscopic
recurrence in Crohn’s disease from the MULTIPER database. Digestive Disease Week
(DDW) 2014. Chicago, USA. May 4, 2014.
129. Kotze PG, Yamamoto T, Danese S, Suzuki Y, Albuquerque IC, Barcelos IF, Kotze
LM, Olandoski M, Teixeira FV, Silva RN, Sacchi M, Yamada A, Saad-Hossne R,
Spinelli A. Does the location of an IBD centre impact the rates of early postoperativeendoscopic recurrence after ileocecal resection in Crohn’s disease? Results from the
MULTIPER database. Digestive Disease Week (DDW) 2014. Chicago, USA. May 4,
2014.
130. Yamamoto T. Nutrition and diet in IBD patients. The 2nd Annual Meeting of Asian
Organization for Crohn’s & Colitis. Seoul, Korea. June 21, 2014.
131. Yamamoto T, Umegae S, Matsumoto K. Safety and feasibility of hand-assisted
laparoscopic surgery for ulcerative colitis. 14th World Congress of Endoscopic
Surgery. Paris, France. June 28, 2014.
132. Yamamoto T, Umegae S, Matsumoto K. Safety and feasibility of laparoscopic
ileocolonic resection for Crhon’s disease. 14th World Congress of Endoscopic
Surgery. Paris, France. June 28, 2014.
133. Yamamoto T, Nakayama S, Matsumoto K. Hand-assisted laparoscopic versus open
colectomy for ulcerative colitis: safety and feasibility. United European

Gastroenterology Week for 2014 (GASTRO 2014). Vienna, Austria.
October 21, 2014.
134. Yamamoto T, Kotze P, Spinelli A, Suzuki Y, Teixeira F and the MULTIPER Study
Group. Factors affecting the incidence of an early endoscopic recurrence after
ileocolonic resection for Crohn’s disease: a multicentre study. United European
Gastroenterology Week for 2014 (GASTRO 2014). Vienna, Austria.
October 21, 2014.
135. Ogata H, Yamamoto T, Kunisaki R, Ishida K, Hibi T. Efficacy, safety anddemographics factor of oral tacrolimus therapy in 671 Japanese patients withrefractory ulcerative colitis. United European Gastroenterology Week for 2014
(GASTRO 2014). Vienna, Austria. October 21, 2014.
136. Yamamoto T, Shiraki M, Matsumoto K. The impact of mucosal healing on subsequentclinical course in the management of ulcerative colitis: a prospective observational
study. United European Gastroenterology Week for 2014 (GASTRO 2014). Vienna,
Austria. October 22, 2014.
137. Yamamoto T, Shimoyama T, Matsumoto K. The effects of preoperative adsorptive
leukocytapheresis on inflammatory cytokines and septic complications after
restorative proctocolectomy for ulcerative colitis: a prospective randomized study.
10th Congress of ECCO - Inflammatory Bowel Diseases 2015. Barcelona, Spain.
February 20, 2015.
138. Yamamoto T, Shimoyama T, Matsumoto K. Systemic and peritoneal inflammatory
response after laparoscopic vs open emergency colectomy for acute severe ulcerative
colitis. 10th Congress of ECCO - Inflammatory Bowel Diseases 2015. Barcelona,
Spain. February 20, 2015.
139. Yamamoto T, Nakahigashi M, Shimoyama T, Matsumoto K. The long-term efficacy
of concomitant enteral nutritional therapy during maintenance infliximab in patientswith Crohn’s disease: a prospective observational trial. 10th Congress of ECCO Inflammatory Bowel Diseases 2015. Barcelona, Spain. February 20, 2015.
140. Yamamoto T, Himan T, Shimoyama T, Matsumoto K. Hand-assisted laparoscopic
surgery for ulcerative colitis: Safety and feasibility. Minimally Invasive Surgery Week
2015 SLS Annual Meeting & Endo Expo. New York, USA. September 3, 2015.
141. Yamamoto T. Faecal biomarkers and their role in surgery in IBD.
The 5th S-ECCO IBD Masterclass. 11th Congress of ECCO - Inflammatory Bowel
Diseases 2016. Amsterdam, The Netherlands. March 17, 2016.
142. Yamamoto T, Shimoyama T, Matsumoto K. Long-term clinical impact of early
introduction of granulocyte and monocyte adsorptive apheresis in new onset,

moderately active, extensive ulcerative colitis. Japanese Digestive Disease Week
(JDDW) 2015. Tokyo. October 9, 2015.
143. Yamamoto T, Shimoyama T, Matsumoto K. Safety and feasibility of laparoscopic
ileocolonic resection for Crhon’s disease. Japanese Digestive Disease Week (JDDW)
2015. Tokyo. October 9, 2015.
144. Yamamoto T, Shimoyama T, Umegae S, Matsumoto K. Serial monitoring of faecal
calprotectin for the assessment of endoscopic recurrence in asymptomatic patients
after ileocolonic resection for Crohn’s disease: a long-term prospective study. 11th
Congress of ECCO - Inflammatory Bowel Diseases 2016. Amsterdam, The
Netherlands. March 18, 2016.
145. Yamamoto T, Shimoyama T, Umegae S, Matsumoto K. Safety and efficacy of daily
granulocyte and monocyte adsorptive apheresis in 50 consecutive patients with active
ulcerative colitis: a prospective study. 11th Congress of ECCO - Inflammatory Bowel
Diseases 2016. Amsterdam, The Netherlands. March 18, 2016.
146. Yamamoto T, Shimoyama T, Umegae S, Matsumoto K. Tacrolimus vs anti-tumour
necrosis factor agents for moderately to severely active ulcerative colitis: aretrospective observational study. 11th Congress of ECCO - Inflammatory Bowel
Diseases 2016. Amsterdam, The Netherlands. March 18, 2016.
147. Yamamoto T, Shimoyama T, Himan T, Umegae S. The impact of preoperative
immunosuppressive and biologic therapy on complications after surgery for
inflammatory bowel disease. European Society of Coloproctology (ESCP) 11th
Scientific & Annual Meeting. Milan, Italy. September 28-30, 2016.
148. Yamamoto T, Himan T, Shimoyama T, Umegae S. Comparison of the outcomes oflaparoscopic vs conventional open resection for Crhon’s disease. European Society ofColoproctology (ESCP) 11th Scientific & Annual Meeting. Milan, Italy. September
28-30, 2016.
149. Yamamoto T, Tanaka T, Yokoyama T, Shimoyama T, Ikeuchi H, Uchino M, Watanabe
T. Efficacy of granulocyte and monocyte apheresis for antibiotic-refractory pouchitis
after proctocolectomy for ulcerative colitis: An open-label, prospective, multicentre
study. 12th Congress of ECCO - Inflammatory Bowel Diseases 2017. Barcelona,
Spain. February 17, 2017.
150. Yamamoto T, Shimoyama T, Umegae S. Impacts of mucosal healing on clinicaloutcomes in patients with refractory ulcerative colitis on tacrolimus or biologics. 12th
Congress of ECCO - Inflammatory Bowel Diseases 2017. Barcelona, Spain. February
17, 2017.
151. Yamamoto T. Optimised strategies for postoperative management of Crohn’s disease.

IOIBD Annual General Meeting. Stresa, Italy. April 22, 2017.
152. Yamamoto T, Shimoyama T, Umegae S, Matsumoto K. Endoscopic score versus
faecal biomarkers for predicting relapse in patients with ulcerative colitis after clinicalremission and mucosal healing. 13th Congress of ECCO - Inflammatory Bowel
Diseases 2018. Vienna, Austria. February 16, 2018.
153. Yamamoto T, Shimoyama T, Umegae S, Matsumoto K. The value of faecal
biomarkers for screening small bowel inflammation in patients with Crohn’s disease.
13th Congress of ECCO - Inflammatory Bowel Diseases 2018. Vienna, Austria.
February 16, 2018.
154. Yamamoto T, Shimoyama T, Umegae S, Matsumoto K. Surgery for severely active
ulcerative colitis in the era of new medical treatment: the impacts of medications onsurgery avoidance, and short-term and long-term surgical outcomes. 13th Congress of
ECCO - Inflammatory Bowel Diseases 2018. Vienna, Austria. February 16, 2018.
155. Yamamoto T. Nutritional therapy in Asian IBD: Current status. The 6th annual
meeting of Asian Organization for Crohn’s & Colitis. Shanghai, China. June 23, 2018.
156. Yamamoto T. Optimal perioperative management of inflammatory bowel disease in
the era of biologics. Annual Meeting of Society of Colon and Rectal Surgeon 2018.
Tainan, Taiwan. September 8, 2018.
157. Kirchgesner J, Boschetti G, Buisson A, Yamamoto T, Domenech E, Nancey S,
Peyrin-Biroulet L, Uzzan M. Systematic review with meta-analysis of individual data:
impact of cut-off values on the performance of fecal calprotectin to detect endoscopic
recurrence after intestinal resection in patients with Crohn’s disease. 14th Congress of
ECCO - Inflammatory Bowel Diseases 2019. Copenhagen, Denmark. March 8, 2019.
158. Shimoyama T, Yamamoto T, Umegae S, Matsumoto K. The value of faecal
calprotectin for assessing endoscopic activity and predicting future clinical course inpatients with active ulcerative colitis treated with granulomonocytapheresis: A
prospective study. 14th Congress of ECCO - Inflammatory Bowel Diseases 2019.
Copenhagen, Denmark. March 8, 2019.
159. Shimoyama T, Yamamoto T, Umegae S, Matsumoto K. The relationship between
computed tomography enterography findings and levels of faecal biomarkers inpatients with small bowel Crohn’s disease: A prospective study. 14th Congress of
ECCO - Inflammatory Bowel Diseases 2019. Copenhagen, Denmark. March 8, 2019.
160. Yamamoto T, Iida T, Ikeya K, Kato M, Matsuura A, Tamura S, Takano R, Tani S,
Osawa S, Sugimoto K, Shimoyama T, Hanai H. Factors affecting the efficacy of
granulomonocytapheresis in moderately-to-severely active ulcerative colitis: A
multicentre retrospective study. 14th Congress of ECCO - Inflammatory Bowel

Diseases 2019. Copenhagen, Denmark. March 8, 2019.
161. Yamamoto T, Iida T, Ikeya K, Kato M, Matsuura A, Tamura S, Takano R, Tani S,
Osawa S, Sugimoto K, Shimoyama T, Hanai H. Endoscopic evaluation and factors
affecting the endoscopic efficacy during granulomonocytapheresis inmoderately-to-severely active ulcerative colitis: A multicentre retrospective study.
14th Congress of ECCO - Inflammatory Bowel Diseases 2019. Copenhagen,Denmark. March 8, 2019.
162. Kakuta K, Dohi K, Yamamoto T, Fujimoto N, Shimoyama T, Umegae , Ito M.
Coronary microvascular dysfunction in inflammatory bowel disease: Restored after
enterectomy. European Society of Cardiology. Paris, France. 31 Augst, 2019 - 4
September, 2019.
163. Naganuma M, Yokoyama Y, Watanabe K, Motoya S, Sawada K, Hirai F, Yamamoto T,
Omori T, Hanai H, Kanai T, Hibi T, CAPTAIN study group. Efficacy of apheresis as amaintenance therapy in a prospective multicentre randomised controlled trial ofpatients with ulcerative colitis. United European Gastroenterology Week 2019.
Barcelona, Spain. October 21, 2019.
164. Shibuya T, Osada T, Yamamoto T, Shimoyama T, Aoyama N, Mizuno C, Tanaka H,
Hongo H, Masuda T, Hosoi E. Safety and effectiveness of retreatment with
granulocyte and monocyte adsorptive apheresis in patients with inflammatory bowel
diseases: A multicentre cohort study. United European Gastroenterology Week 2019.
Barcelona, Spain. October 21, 2019.
165. Kakuta K, Dohi K, Yamamoto T, Fujimoto N, Shimoyama T, Umegae S, Saito Y, Ito
M. Impact of enterectomy on coronary microcirculation in patients with inflammatory
bowel disease. American Heart Association Scientific Sessions 2019. Philadelphia,
USA. 16-18 November, 2019.
166. Kobayashi T, Motoya S, Nakamura S, Yamamoto T, Nagahori M, Tanaka S,
Hisamatsu T, Hirai F, Nakase H, Watanabe K, Matsumoto T, Tanaka M, Abe T, Suzuki
Y, Watanabe M, Hibi T. The first prospective, mucticentre, randomised controlled trial
on discontinuation of infliximab in ulcerative colitis in remission; endoscopic
normalisation does not guarantee successful withdrawal. 15th Congress of ECCO Inflammatory Bowel Diseases 2019. Vienna, Austria. February 13, 2019.
国内学会報告(主題演題のみ)
1. 山本隆行, 松本好市, 東 崇明, 三木誓雄, 北川達士, 山本純二, 入山圭司, 鈴
木宏志. シンポジウム「クローン病の栄養療法, 手術法からみた長期経過」：クローン病長期経過例の検討. 第51回日本大腸肛門病学会. 1996年10月25,26日, 青森

2. 捨田利外茂夫, 山本隆行, Keighley MRB. パネルディスカッション「炎症性腸疾
患」：クローン病の狭窄に対する20cm以上の狭窄形成術の安全性と有用性. 第104回日本外科学会定期学術集会. 2004年4月7日, 大阪
3. 山本隆行. 特別講演「IBD治療, 栄養管理の日本およびアメリカにおける現状と今後の方向性. クリーブランドクリニックでの経験から」. 第53回日本栄養改善学会学術集会. 第9回自由集会「クローン病の食事療法を考える会」. 2006年10月25日, 筑波
4. 山本隆行. ランチョンセミナー: クローン病に対する経腸栄養療法の再評価 －緩解導入および維持効果−. 第93回日本消化器病学会総会. 2007年4月19-21日, 青森
5. 山本隆行, 梅枝 覚, 松本好市. パネルディスカッション: クローン病の長期緩解維持をめざして. クローン病術後再発に関与する因子とEvidence Based Medicineに基づく再発予防策: Systematic Literature Review. 第93回日本消化器病学会総会.
2007年4月19-21日, 青森
6. 山本隆行, 梅枝 覚, 松本好市. パネルディスカッション: 血球成分除去療法の世
界標準治療法確立に向けて －基礎および臨床からの発信－ Selective
Leukocytapheresisの潰瘍性大腸炎患者の大腸粘膜の炎症に及ぼす作用について:
Mucosal Cytokine ProfilesとEndoscopic Findings. 第93回日本消化器病学会総会.
2007年4月19-21日, 青森
7. 山本隆行. ランチョンセミナー：クローン病における長期緩解を目指した栄養療法～最新のエビデンスを求めて～. 第11回日本病態栄養学会年次学術集会. 2008年
1月12日, 京都
8. 山本隆行, 中東 真紀, Abbi Saniabadi, 岩田 崇, 丸山 泰貴, 梅枝 覚, 松本 好
市. 小越章平記念 Best Paper in 2007 受賞講演：緩解期クローン病患者における長期の経腸栄養療法の臨床的および内視鏡的効果と粘膜内のサイトカイン産生におよぼす影響について：前向き比較試験. 第23回日本静脈経腸栄養学会. 2008年2月21日, 京都
9. 山本隆行, 梅枝 覚, 松本好市. シンポジウム「クローン病の長期予後：本邦のエビデンスを求めて」：緩解期クローン病に対する長期経腸栄養療法の臨床的および内視鏡効果: 前向き比較試験. 第94回日本消化器病学会総会. 2008年5月8日, 福岡
10. 山本隆行. ランチョンセミナー「顆粒球吸着療法による炎症制御の意義」：潰瘍性大腸炎患者の大腸粘膜における顆粒球吸着療法の炎症抑制作用について：内視鏡所見と粘膜サイトカイン産生量の検討. 第53回日本透析医学会学術集会・総会.
2008年6月21日, 神戸
11. 山本隆行, 梅枝 覚, 松本好市. パネルディスカッション「クローン病の手術適応と再燃をめぐって」：クローン病における初回手術時の手術適応(穿孔型/非穿孔型)と術後再発率および再発形式との関連 －Meta-Analysis－. 第16回日本消化器関連
学会週間 (JDDW 2008). 2008年10月3日, 東京
12. 山本隆行, 梅枝 覚, 松本好市. ワークショップ「絞扼性イレウスの早期診断」：腸閉塞患者において血漿サイトカインの測定は腸管絞扼の早期診断に有用か? －前向き臨床試験－. 第70回日本臨床外科学会総会. 2008年11月27日, 東京
13. 山本隆行, 中東真紀, 梅枝 覚, 松本好市. 栄養管理フォーラム「クローン病に対する栄養療法」：クローン病の緩解維持に経腸栄養療法は有効か？ －当院の臨床試験の結果から－. 第5回日本消化管学会総会学術集会. 2009年2月12日, 東京
14. 山本隆行, 梅枝 覚, 松本好市. パネルディスカッション「クローン病小腸病変の評
価とその治療」：クローン病切除術後早期の吻合部回腸側の内視鏡所見と臨床的再発率との関連：A Prospective Endoscopic Cohort Study. 第95回日本消化器病学会
総会. 2009年5月8日, 札幌
15. 山本隆行. シンポジウム「クローン病の栄養療法 ～栄養療法のエビデンスと栄養指導の実際～」：クローン病において術後経腸栄養療法は再発防止に有用か? －前向き臨床試験による検証－. 第31回日本臨床栄養学会総会. 2009年9月19日, 神戸
16. 山本隆行. ランチョンセミナー「粘膜治癒から見た消化管の治療」：経腸栄養療法のクローン病粘膜病変に対する炎症抑制効果. 第17回日本消化器関連学会週間(JDDW 2009). 2009年10月16日, 京都
17. 山本隆行, 梅枝 覚, 松本好市. シンポジウム「炎症性腸疾患の病態に立脚した治療法の開発」：クローン病術後早期の内視鏡病変に対するインフリキシマブの有効性：A Prospective Study. 第17回日本消化器関連学会週間 (JDDW 2009). 2009年
10月16日, 京都
18. 山本隆行. ランチョンセミナー「アダカラム再発見 －10年の時を経て－」：炎症性腸疾患におけるGCAPの臨床効果とその位置づけ －当院での経験から－. 第64回日
本大腸肛門病学会学術集会. 2009年11月6日, 福岡
19. 山本隆行, 梅枝 覚, 松本好市. シンポジウム「炎症性腸疾患の治療：本邦でのエビデンスを求めて」: Prospective Studyによるインフリキシマブのクローン病術後再発予防効果の検証：Evidenceに基づいた再発予防のアルゴリズム作成を目指して. 第64回日本大腸肛門病学会学術集会. 2009年11月6日, 福岡
20. 山本隆行, 梅枝 覚, 松本好市. ワークショップ「インフリキシマブ投与クローン病の経過（肛門部病変を含む）」：インフリキシマブによる寛解維持療法中のクローン病患者に対する経腸栄養療法の再燃抑制効果：A Prospective Pilot Trial. 第64回日本
大腸肛門病学会学術集会. 2009年11月7日, 福岡
21. 山本隆行, 梅枝 覚, 松本好市. シンポジウム「IBDに対する鏡視下手術の現状と問題点」：重症潰瘍性大腸炎に対する緊急用手補助下腹腔鏡手術(HALS)の安全

性と有効性. 第64回日本大腸肛門病学会学術集会. 2009年11月7日, 福岡
22. 山本隆行, 梅枝 覚, 松本 好市. シンポジウム 「Crohn病の長期予後改善を目指して」：クローン病寛解維持療法におけるインフリキシマブおよび経腸栄養療法の有効性と位置づけ. 第96回日本消化器病学会総会. 2010年4月22日, 新潟
23. 山本隆行, 梅枝 覚, 松本 好市. パネルディスカッション 「病態からみた炎症性腸疾患の新しい治療選択」：潰瘍性大腸炎患者における顆粒球除去療法の粘膜治癒効果とその臨床的意義：A Prospective Cohort Study. 第18回日本消化器関連学会
週間 (JDDW 2010). 2010年10月14日, 横浜
24. 山本隆行, 梅枝 覚, 松本 好市. シンポジウム 「Crohn病の術後再発とその対策」：クローン病術後再発高リスク患者に対するインフリキシマブの再発予防効果：A
Prospective Observational Study. 第18回日本消化器関連学会週間 (JDDW 2010).
2010年10月15日, 横浜
25. 山本隆行. ランチョンセミナー：クローン病の術後再発予防対策 －エビデンスに基づいて－. 第11回日本小児IBD研究会. 2011年2月13日, 大阪
26. 山本隆行, 梅枝 覚, 松本好市. シンポジウム「日本から発信するIBD治療の工夫と標準化」：Biological Eraにおけるクローン患者に対する経腸栄養療法の意義. 第97回日本消化器病学会総会. 2011年5月14日, 東京
27. 山本隆行. ランチョンセミナー「Inflammatory Bowel Disease －内視鏡的粘膜治癒を目指して－」：メサラジン低用量寛解維持療法中に再燃した潰瘍性大腸炎患者にメサラジンの増量は有効か? 第81回日本消化器内視鏡学会総会. 2011年8月18日,
名古屋
28. 山本隆行, 梅枝 覚, 松本好市. ビデオシンポジウム｢IBDのよりよい外科治療とは－鏡視下か開腹か－｣：炎症性腸疾患に対する用手補助下腹腔鏡手術(HALS)の治療成績. 第66回日本大腸肛門病学会学術集会. 2011年11月25日, 東京
29. 山本隆行, 梅枝 覚, 松本好市. シンポジウム｢IBDに対する薬物治療の進歩と課
題｣：潰瘍性大腸炎再燃例に対するメサラジン高用量治療の安全性と有効性: 前向き臨床試験. 第66回日本大腸肛門病学会学術集会. 2011年11月26日, 東京
30. 山本隆行. ランチョンセミナー｢顆粒球吸着療法の可能性 －より良いQOLを目指して－｣：潰瘍性大腸炎に対するGCAP連続5日法の安全性と有効性. 第66回日本大
腸肛門病学会学術集会. 2011年11月26日, 東京
31. 山本隆行, 梅枝 覚, 松本好市.シンポジウム「炎症性腸疾患の診療における画像診断の役割」：クローン病切除術後の早期の内視鏡所見の臨床的意義. 第54回日
本消化器内視鏡学会東海地方会. 2011年12月10日, 浜松
32. 梅枝 覚, 松本好市, 北川達士, 野地みどり, 山本隆行, 石井雅昭, 肥満智紀,成田 清, 鳥井孝宏, 湯澤浩之, 山崎 学. シンポジウム「痔瘻に対する低侵襲外科療法」：根治性と括約筋温存を考慮した痔瘻根治術式の選択. 第66回日本大腸肛門病学会学術集会. 2011年11月25日, 東京
33. 山本隆行, 梅枝 覚, 松本好市. パネルディスカッション「IBDにおける粘膜治癒の位置づけ」：潰瘍性大腸炎に対する顆粒球除去療法の粘膜治癒効果：粘膜治癒達成率と臨床経過に与える影響. 第83回日本消化器内視鏡学会総会. 2012年5月13日, 東京
34. 白木 学, 山本隆行, 松本好市. パネルディスカッション「消化吸収の側面からみた
炎症性腸疾患の病態と栄養療法」：難治性クローン病患者におけるインフリキシマブの有効性と栄養状態(BMI)改善効果：前向き臨床試験. 第20回日本消化器関連学会週間 (JDDW 2012). 2012年10月10日, 神戸
35. 山本隆行. ランチョンセミナー｢有効治療から炎症性腸疾患の病態を学ぶ －粘膜治癒・顆粒球・サイトカインに着目して－｣：顆粒球吸着療法早期導入による潰瘍性大腸炎の長期成績 －ステロイド減量および依存症回避効果－. 第20回日本消化器関連学会週間 (JDDW 2012). 2012年10月11日, 神戸
36. 白木 学, 山本隆行, 梅枝 覚, 松本好市. シンポジウム「IBD診療における外科と内科の接点(難治症例の治療方針)」：クローン病術後再発予防のStrategy:
Endoscopic Monitoring + Treatment Step-up. 第67回日本大腸肛門病学会学術集会. 2012年11月16日, 福岡
37. 山本隆行. ランチョンセミナー：生物学的製剤がクローン病手術に与えたインパクト:
術後合併症のリスクと再発予防効果. 第67回日本大腸肛門病学会学術集会. 2012
年11月16日, 福岡
38. 山本隆行, 白木 学, 梅枝 覚, 松本好市. ワークショップ｢潰瘍性大腸炎の術後成績とQOL評価｣：潰瘍性大腸炎の術後合併症と排便機能に関与する因子. 第67回
日本大腸肛門病学会学術集会. 2012年11月17日, 福岡
39. 山本隆行. ランチョンセミナー｢日常臨床で役立つIBD治療の勘所｣：外科医に知ってもらいたい再燃・再発予防の工夫. 第67回日本大腸肛門病学会学術集会. 2012
年11月17日, 福岡
40. 山本隆行, 中東真紀. シンポジウム「クローン病の栄養療法」：前向き試験による経腸栄養療法のクローン病術後再発予防効果: 術後5年間追跡結果. 第28回日本静脈経腸栄養学術集会. 2013年2月22日, 金沢
41. 山本隆行. ワークショップ「病態別経腸栄養法 ～経腸栄養剤をいかに活用するか～」：炎症性腸疾患における経腸栄養療法のエビデンス. 第35回日本臨床栄養学
会総会. 2013年10月4日, 京都
42. 山本隆行, 白木 学, 馬場卓也, 中山茂樹, 梅枝 覚, 松本好市. シンポジウム「難治性潰瘍性大腸炎の治療選択 (寛解導入と寛解維持)」：難治性潰瘍性大腸炎に対する顆粒球除去療法の集中治療：連続5日法の安全性と有効性. 第68回日本大
腸肛門病学会学術集会. 2013年11月15日, 東京

43. 山本隆行, 白木 学, 馬場卓也, 中山茂樹, 梅枝 覚, 松本好市. パネルディスカ
ッション「クローン病の術後治療をどうするか?」：クローン病の術後再発予防におけるEndoscopic Monitoringの重要性. 第68回日本大腸肛門病学会学術集会. 2013年11月16日, 東京
44. 山本隆行. ランチョンセミナー「クローン病治療におけるアダリムマブの役割 －術後治療・肛門部病変を中心に」：第68回日本大腸肛門病学会学術集会. 2013年11月15日, 東京
45. 山本隆行. イブニングセミナー：タクロリムスを用いた潰瘍性大腸炎に対する治療戦
略 －外科医の視点から－. 第68回日本大腸肛門病学会学術集会. 2013年11月15日, 東京
46. 白木 学, 山本隆行, 梅枝さとる, 松本好市. シンポジウム「消化管疾患における診断・治療のup to date」：潰瘍性大腸炎活動期におけるlow dose CTの有用性. 日本
消化器病学会総会東海支部第120回例会. 2014年6月14日, 岐阜
47. 山本隆行, 鈴木康夫. パネルディスカッション「IBDに対する外科治療の位置づけ」：クローン病における術前免疫抑制療法と術後合併症のリスクとの関連: 国際多施設共同研究. 第69回日本消化器外科学会総会. 2014年7月17日, 郡山
48. 山本隆行, 白木 学, 松本好市. シンポジウム「難治性クローン病: 病態から考えた治療アプローチ」：クローン病術後再発のモニタリングと薬剤治療の最適化. 第22回
日本消化器関連学会週間 (JDDW 2014). 2014年10月23日, 神戸
49. 山本隆行, 白木 学, 松本好市. 統合プログラム「炎症性腸疾患における内科・外科の接点」：炎症性腸疾患における術前の免疫抑制療法と術後合併症のリスクとの関連について. 第22回日本消化器関連学会週間 (JDDW 2014). 2014年10月25日,
神戸
50. 山本隆行, 馬場卓也, 松本好市. シンポジウム「難治性クローン病: 病態から考えた治療アプローチ」：術前血球成分除去療法による潰瘍性大腸炎術後感染性合併症および回腸嚢炎の発生予防の試み: ランダム化比較試験. 第22回日本消化器関連学会週間 (JDDW 2014). 2014年10月26日, 神戸
51. 山本隆行. ランチョンセミナー「クローン病治療におけるヒュミラの可能性」：術後管理をどうするか? 第22回日本消化器関連学会週間 (JDDW 2014). 2014年10月26日,
神戸
52. 山本隆行, 白木 学, 松本好市. シンポジウム「炎症性腸疾患の治療戦略」：難治性潰瘍性大腸炎に対するタクロリムス治療の寛解導入効果と手術回避効果. 第69回
日本大腸肛門病学会学術集会. 2014年11月7日, 横浜
53. 山本隆行, 梅枝 覚, 松本好市. ビデオシンポジウム「ビデオチュートリアル IBDの手術」：炎症性腸疾患に対する用手補助下腹腔鏡手術(HALS)による大腸切除. 第69回日本大腸肛門病学会学術集会. 2014年11月8日, 横浜

54. 山本隆行, 白木 学, 松本好市. シンポジウム「生物学的製剤時代におけるクロー
ン病のトータルマネージメント」：インフリキシマブ寛解維持療法中のクローン病患者に対する経腸栄養療法の再燃抑制効果：長期前向きコホート研究. 第101回日本消化器病学会総会. 2015年4月23日, 仙台
55. 山本隆行, 白木 学, 松本好市. パネルディスカッション「難治性潰瘍性大腸炎の適切な治療選択とは?」：難治性潰瘍性大腸炎に対するタクロリムスおよび生物学的製剤の寛解導入効果と手術回避効果. 第101回日本消化器病学会総会. 2015年4月25日, 仙台
56. 山本隆行, 梅枝 覚, 松本好市. ワークショップ「IBD治療戦略における内視鏡の役
割」：クローン病術後早期の内視鏡所見と臨床的再発率との関連：長期前向きコホート研究. 第89回日本消化器内視鏡学会総会. 2015年5月29日, 名古屋
57. 山本隆行. ランチョンセミナー：新規バイオマーカーでIBDの再燃・再発は予見できる ～より適切な治療介入と強化を求めて～. 第89回日本消化器内視鏡学会総会.
2015年5月30日, 名古屋
58. 山本隆行. ランチョンセミナー「クローン病のトータルマネジメントを目指して」：術後治療ストラテジーの最適化を目指して. 第70回日本大腸肛門病学会学術集会.
2015年11月13日, 名古屋
59. 山本隆行. ランチョンセミナー：新しいバイオマーカーを用いたIBD活動性のモニタ
リングと治療の最適化. 第58回日本消化器内視鏡学会東海支部例会. 2015年12月5日, 名古屋
60. 山本隆行, 下山貴寛, 梅枝 覚. シンポジウム「炎症性腸疾患の既存治療を徹底的に見直す」：炎症性腸疾患における経腸栄養療法のエビデンスと今後の展望. 第102回日本消化器病学会総会. 2016年4月22日, 東京
61. 山本隆行, 下山貴寛, 梅枝 覚. パネルディスカッション「粘膜治癒を目指したIBDの治療戦略」：難治性潰瘍性大腸炎に対する薬剤療法中の粘膜治癒達成がその後の臨床経過に与える影響について. 第24回日本消化器関連学会週間 (JDDW
2016). 2016年11月3日, 神戸市
62. 山本隆行, 下山貴寛, 梅枝 覚. パネルディスカッション「生物製剤抵抗性炎症性腸疾患の治療方針をめぐって」：生物学的製剤およびタクロリムス治療抵抗性の重症
潰瘍性大腸炎に対する治療成績. 第24回日本消化器関連学会週間 (JDDW
2016). 2016年11月4日, 神戸市
63. 山本隆行. ブレックファーストセミナー：便中炎症マーカーを用いたIBDの新しい治療戦略. Novel strategy for IBD treatment using fecal biomarkers. 第24回日本消化器関連学会週間 (JDDW 2016). 2015年11月4日, 神戸市
64. 山本隆行. ランチョンセミナー：潰瘍性大腸炎治療におけるGMA導入のタイミング.
第24回日本消化器関連学会週間 (JDDW 2016). 2016年11月4日, 神戸市

65. 山本隆行, 下山貴寛, 肥満智紀, 梅枝 覚. シンポジウム「IBD内科治療のForefront」難治性潰瘍性大腸炎におけるタクロリムスと生物学的製剤の安全性と有効性の比較. 第71回日本大腸肛門病学会学術集会. 2016年11月19日, 伊勢市
66. 梅枝 覚, 下山貴寛, 山本隆行. パネルディスカッション「IBDの腸管合併症および腸管外合併症のマネージメントと工夫―内科・外科治療の接点」：非侵襲検査を用いたクローン病術後再発のモニタリングの工夫:前向きコホート研究. 第103回日本
消化器病学会総会. 2017年4月22日, 東京
67. 山本隆行, 下山貴寛, 梅枝 覚. パネルディスカッション「内視鏡によるIBDの治療
効果予測 Endoscopic prediction of the therapeutic effect in IBD patients」：顆粒球除去療法は深い潰瘍性病変には効きにくい. 第93回日本消化器内視鏡学会総会.
2017年5月12日, 大阪
68. 山本隆行. ランチョンセミナー：新規バイオマーカーを用いたIBDの治療戦略 －便
中カルプロテクチンは内視鏡検査に取って代わりうるか?－. 第118回日本消化器内視鏡学会中国支部例会. 2017年6月25日, 広島市
69. 山本隆行. サテライトシンポジウム「難治性潰瘍性大腸炎の治療戦略 ～外科治療を考慮した薬剤療法～」：手術適応と時期の決定：内科と外科の連携の重要性. 第25回日本消化器関連学会週間 (JDDW 2017). 2017年10月14日, 福岡市
70. 山本隆行, 田中敏明, 横山 正, 下山貴寛, 池内浩基, 内野 基, 渡邉聡明. シン
ポジウム「現在の炎症性腸疾患治療に対するCAPの位置づけと工夫」：潰瘍性大腸炎術後の難治性Pouchitisに対するCAP療法の有用性: 多施設共同前向き研究. 第38回日本アフェレーシス学会学術大会. 2017年10月21日, 千葉県浦安市
71. 山本隆行, 下山貴寛, 梅枝 覚. シンポジウム「IBDに対する内科治療の進歩と外科治療」：重症潰瘍性大腸炎に対する薬剤治療の進歩と手術治療の変遷. 第72回
日本大腸肛門病学会学術集会. 2017年11月10日, 福岡市
72. 山本隆行. モーニングセミナー「難治性クローン病の薬物療法を考える」：周術期・術後マネジメント. 第72回日本大腸肛門病学会学術集会. 2017年11月11日, 福岡
市
73. 山本隆行, 田中敏明, 横山 正, 下山貴寛, 池内浩基, 内野基, 渡邉聡明. パネ
ルディスカッション「IBDに対する新しい治療とその応用」：潰瘍性大腸炎術後の抗菌剤抵抗回腸嚢炎に対する顆粒球単球除去療法の安全性と有効性：多施設共同前
向き研究. 第72回日本大腸肛門病学会学術集会. 2017年11月11日, 福岡市
74. 下山貴寛, 山本隆行, 梅枝 覚. ワークショップ「大腸・小腸疾患に対する診断の進
歩」：便中炎症マーカーはクローン病小腸病変の診断に有効か？ 第72回日本大腸肛門病学会学術集会. 2017年11月11日, 福岡市
75. 山本隆行. ランチョンセミナー「IBD治療の新時代における抗TNF製剤の意義」：クローン病治療におけるTreat to Targetの意義. 第104回日本消化器病学会総会. 2018

年4月21日, 東京
76. 山本隆行. 会長特別セッション： 特別発言. 第72回手術手技研究会. 2018年5月12日, 鳴門市77. 山本隆行. サテライトシンポジウム「Biologics時代における内科医と外科医の診療科連携」：クローン病の外科的治療戦略～周術期管理と術後再発予防の最適化. 第26回日本消化器関連学会週間 (JDDW 2018). 2018年11月1日, 神戸市
78. 山本隆行, 杉本 健, 花井洋行. パネルディスカッション「炎症性腸疾患における既存治療を見直す」：中等症および重症潰瘍性大腸炎に対する顆粒球単球吸着除去療法の有効性に関与する臨床因子の検討：多施設共同後ろ向き試験. 第26回日本
消化器関連学会週間 (JDDW 2018). 2018年11月3日, 神戸市
79. 山本隆行, 下山貴寛, 梅枝 覚. ワークショップ「潰瘍性大腸炎緩解維持療法の現状」：Deep Remission達成潰瘍性大腸炎患者における時間依存型メサラジンの寛解維持効果と再燃予測因子の検討. 第73回日本大腸肛門病学会学術集会. 2018年
11月9日, 東京
80. 山本隆行, 下山貴寛, 梅枝 覚. パネルディスカッション「IBDに対する薬物療法の長期成績」：難治性潰瘍性大腸炎に対する薬剤療法の長期成績: 粘膜治癒達成が寛解維持と手術回避に与える影響. 第73回日本大腸肛門病学会学術集会. 2018年
11月10日, 東京
81. 山本隆行, 下山貴寛, 梅枝 覚. シンポジウム「難治性潰瘍性大腸炎の治療戦略における外科と内科のコラボレーション」：難治性潰瘍性大腸炎におけるThird Line
Rescue治療としての生物学的製剤およびタクロリムスの手術回避効果. 第105回日
本消化器病学会総会. 2019年5月11日, 金沢
82. 山本隆行. ランチョンセミナー「外科・内科の立場から考えるクローン病の治療戦略」：クローン病周術期管理の最適化とT2Tに基づく再発予防戦略. 第74回日本大
腸肛門病学会学術集会. 2019年10月11日, 東京
83. 山本隆行, 下山貴寛, 梅枝 覚. パネルディスカッション「専門領域の連携による炎
症性腸疾患の治療」：バイオ製剤による免疫抑制状態のIBD患者における術前栄養評価の重要性について. 第74回日本大腸肛門病学会学術集会. 2019年10月12日,
東京
84. 山本隆行, 下山貴寛, 梅枝 覚. パネルディスカッション「潰瘍性大腸炎治療の現状とこれから」：新しいバイオマーカーを用いた潰瘍性大腸炎術後回腸嚢炎の発症予測と早期診断. 第27回日本消化器関連学会週間 (JDDW 2019). 2019年11月21日, 神戸
85. Yamamoto T, Shimoyama T, Umegae S. International Session (Symposium) 「クローン病術後再発予防に向けた取り組みについて (Management of Crohn’s disease toprevent postoperative recurrence)」：The impact of early endoscopic lesions on theclinical course of patients after ileocolonic resection for Crohn’s disease: a 5-year
prospective cohort study. 第27回日本消化器関連学会週間 (JDDW 2019). 2019年
11月23日, 神戸
86. 山本隆行. サテライトシンポジウム「IBDにおけるバイオマーカーの活用 －NUDT15
遺伝子多型と便中カルプロテクチン」：便中カルプロテクチンによるIBD治療の最適化 ～当院での臨床研究から～. 第27回日本消化器関連学会週間 (JDDW 2019).
2019年11月23日, 神戸